Role of *chrna5* in multi-substance preference and phenotypes comorbid with the development of substance dependence

Authors

Tanisha Goel [1#], Joshua Raine [1#], Caroline Kibat [1], Jeff Winxin Collado [2], Tirtha Das Banerjee [3], Ajay S. Mathuru [1, 2, 4, 5, 6 *]

Affiliations

1. Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
2. Yale-NUS College, National University of Singapore, Singapore, Singapore
3. Department of Biological Sciences, National University of Singapore, Singapore, Singapore
4. Institute for Digital Medicine (WisDM), Yong Loo Lin School of Medicine, National University of Singapore, Singapore
5. Institute of Molecular and Cell Biology, A*STAR, Singapore, Singapore
6. Healthy Longevity Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

*Correspondence: ajay.mathuru@nus.edu.sg # Co-first authors

Abstract

Addiction to nicotine and alcohol continues to be a leading cause of death and loss of productivity as measured in disability-adjusted life years. Polymorphisms in the nicotinic acetylcholine receptor subunit α5 (CHRNA5) have been identified as risk factors associated with nicotine dependence in human genetic studies and rodent models. Whether the *chrna5* function is independently relevant to phenotypes associated with disorders comorbid with substance use, and if genetic factors influence subsequent outcomes when exposure to psychoactive substances happens at an early age, are questions of interest. We generated a stable mutant line in zebrafish using the CRISPR-Cas9 technique. We found that the *chrna5* mutant fish exhibit an increased acute preference to both nicotine and alcohol in the Self-Administration Zebrafish Assay (SAZA). When subjected to multi-day exposures to either, *chrna5* mutants exhibited greater behavioural change, but reduced transcriptomic changes compared to WT siblings, suggesting an impaired homeostatic regulation following drug exposure. Further, *chrna5* mutants exhibited drug-independent changes in appetite and circadian rhythms, suggesting a genetic predisposition to disorders often comorbid with substance dependence. We expect these results to give new insights into the operation of genes whose normal function modulates vulnerability to multi-substance use and comorbid disorders.

Keywords:

Zebrafish, Nicotine Dependence, Alcohol Use Disorders, SUD, Hormesis, *CHRNA5*

Introduction

Substance Use Disorders (SUDs), due to the abuse of nicotine, alcohol, and opioids, are a major global health burden today, with an estimated 162.5 million disability-adjusted life years lost to them globally in 2016 [1–3]. The direct death toll from tobacco alone is predicted to exceed 8 million per year by 2030 [4,5], with cancers, cardiovascular diseases, and chronic obstructive pulmonary disorders as the major disease outcomes [6]. The development of dependence leading to these outcomes is influenced by a complex mix of socio-economic, cultural, neurobiological, and genetic factors that is challenging to untangle [7,8].

A particularly vulnerable period of substance exposure is early age, when the still-developing brain undergoes significant neurodevelopmental and neuroanatomical changes. Exposure during this critical window can lead to profound alterations in brain structure and gene expression that can be long-lasting [9,10]. Genetic variation contributes to differences in individual susceptibility, both for the consequences of exposure at an early age and the risk of developing SUDs subsequently [9]. Research aimed towards isolating the genetic components has revealed strong associations between polymorphisms in nicotinic acetylcholine receptor subunit genes (nAChRs) and nicotine use [8]. In particular, the gene cluster *CHRNA5-CHRNA3-CHRNB4* encoding for the α5, α3, and β4 subunits has been frequently identified in genome-wide association studies [11–16].

In rodents, where *Chrna5* function has been examined extensively [17], expression across many regions of the brain, including medial habenula-IPN pathway [18] and ventral tegmental area (VTA [19]) is documented. These regions are proposed to impact withdrawal behaviours and nicotine dependence [20]. Manipulation of *Chrna5* levels within them has been shown to alter nicotine preference [18,21]. In addition to nicotine, polymorphisms in the *CHRNA5-CHRNA3-CHRNB4* locus have also been correlated with vulnerability to alcohol dependence [22,23], despite alcohol not being a direct ligand [23–26]. As co-abuse of nicotine and alcohol is common [27], elucidation of the interdependent relationships represents an important step towards conceiving holistic interventions. Multi-day exposure to nicotine and alcohol impacts both the transcriptional profile and behaviour, and it is equally important to understand the neuroadaptive changes in the brain that influence behaviour [28–30]. Furthermore, the harmful outcomes of SUDs are not limited to addiction, as neurophysiological disorders of anxiety, sleep, and appetite control often occur comorbidly [31]. Therefore, understanding the mechanisms underlying the initial stages of dependence, at an age when brains are still developing, is crucial for the design of interventional strategies informed by genetic predisposition.

71 Untangling the contribution of genetic predisposition to induction of these comorbid disorders is
72 challenging to discover in humans, however, due to the bidirectional nature of the relationships
73 between drug use and neuroplasticity, and ethical considerations, such as assigning an adolescent to
74 drug exposure in a randomized control trial. In this context, animal models can be effective
75 intermediates to bridge the gap in our knowledge. In addition to the mammalian models, the zebrafish
76 represents a viable alternative to study neurogenetics, thanks to the established conservation of
77 function and anatomy [32–34], cost effectiveness, efficient genetic manipulation, and live, whole brain
78 neural activity imaging [35]. At the same time, a battery of behavioural assays to rapidly examine
79 anxiety-like behaviours [36], circadian rhythms [37], and appetite [38] are now available. New assays to
80 examine not just the effect of psychoactive substances [39], but also the natural responses [40–43] add
81 to their value for neurogenetic studies.

82 Here, we generated a zebrafish *chrna5* mutant line using CRISPR-Cas9 technique to study transcriptomic
83 and behavioural change after exposure to substances of abuse at an early age. In drug preference
84 assays, homozygous *chrna5* mutant juvenile fish phenocopied adult rodent responses, exhibiting
85 increased acute, naive self-administration of both nicotine and alcohol. This recapitulation validates the
86 use of this model system to study the neurogenetics of development of SUDs. Multiday, pre-exposure
87 experiments revealed the modulation of preference, with greater influence on *chrna5* mutant
88 behaviour, while homeostatic transcriptomic changes reduced behavioural changes in WT animals.
89 *chrna5* mutants were also impaired in circadian rhythm and appetite regulation, with no effect on
90 anxiety-like behaviours. This study thus adds to our knowledge of α5 nicotinic acetylcholine receptors in
91 the development of SUDs and the potential consequences of manipulating its function as an
92 intervention.

93

Results


a
N-L
COOH
Extracellular
Intracellular
5bp deletion
WT
chrna5-/-
b
WT
chrna5-/-
NH2
COOH
Extracellular
Intracellular
TM2
TM1
TM3
TM4
5bp deletion
c
WT
chrna5-/-
Relative Express on
n = 7
n = 8
Cliff's delta
d
Prosencephalon
Rhombencephalon
Pineal gland & Habenula
OB
Eye
Tel
dHbL
Pl
dHbR
Tor
TeO
Ce
imMO
ifMO
DAPI
nrp1a
chrna5
merge
Rostral
Caudal
dHb
50µm
20µm

Figure 1. Characterisation of *chrna5* mutant zebrafish. (**a**) Schematic representation of chrna5 transmembrane helices. The red line indicates the stop codon present in the mutants between the third and fourth transmembrane regions. Mutants had a 5 bp deletion in exon 8 at position 10, resulting in a premature termination codon at amino acid 334 (UniProt entry Q567Y7_DANRE). (**b**) Predicted tertiary protein structure of chrna5 in WT and *chrna5* mutants, generated by Alphafold [44]. (**c**) Fold change of *chrna5* mRNA in WT (n = 7) vs. *chrna5* mutants (n = 8) whole brain tissue by qPCR. See table S3 for the precise effect size and p-values. (**d**) Gene expression patterns in 14 dpf larval zebrafish brains visualised by HCR^{TM} RNA-FISH (HCR). Schematic images with regional markers (v2.0, MECE, 2024) were generated in mapZeBrain Atlas (mapzebrain.org, Jan 2025) (Kunst et al., 2019). Hb = habenula, vHb = ventral habenula, Ipn = interpeduncular nucleus, Omn = oculomotor nucleus, Trm = trochlear motor nucleus, Ni = nucleus isthmi, Vmn = vagus motor nucleus, srFmn = supra-rostral Fmn, rFmn = rostral Fmn, cFmn = caudal Fmn.

The *chrna5* mutant zebrafish generated for this study by CRISPR-Cas9 had a five-base pair deletion in exon 8, resulting in a premature termination codon at amino acid position 334 (Figure 1 (**a**)). This stop codon was predicted to truncate the protein at the intracellular loop between the third and fourth transmembrane regions (Figure 1(**b**)). In addition to the functional inhibition stemming from the introduction of a premature termination codon, we also examined the stability of the expression profile by quantitative RT-PCR of the adult whole brain. This examination indicated a small, but non-significant, reduction in the expression of *chrna5* transcripts in the mutants (Figure 1 (**c**), WT vs. *chrna5*, Cliff's delta = -0.438, 95CI [0.156, -0.875], p = 0.122). The reduction of *chrna5* mRNA expression resulted in a corresponding downstream reduction in the relative abundance of chrna5 protein levels in adult brains (Figure S5). The expression of *chrna3* and *chrnb4* was unchanged (Figure S1). *Chrna5* expression in mice has been reported in the habenula-interpeduncular nucleus (IPN) circuit in addition to the ventral tegmental area (VTA), relevant to nicotine aversive responses [17,45]. In zebrafish, *chrna5* mRNA expression has been reported in the ventral IPN as well [46], while chrna5 protein in a recently established transgenic line has been reported to be broader, in the pineal gland, stratum periventricular of the optic tectum, corpus cerebellum, and hindbrain motor neurons [47]. We examined the expression of zebrafish *chrna5* in 14 dpf larvae using RAM-FISH method developed in-house [48]. This analysis revealed that neurons in the telencephalon, torus longitudinalis, cerebellum, and hindbrain exhibited the highest expression, but low levels of *chrna5* expression were visible in the majority of brain regions, including the dorsal habenula (Figure 1(**d**) and S2-4).


a
Self Administration for Zebrafish Assay (SAZA)
3.5 cm
7.5 cm
In
Out
Stimulus ROI
Control ROI
Stimulus
Control
Self-admin (18')
Pre (3')
Post (3')
Volume dispensed (Vol)
(Stimulus Vol - Control Vol)
(Stimulus Vol + Control Vol)
=
Preference Index
-1.0
+1.0
Control
Stimulus
SAZA
WT 0μM Nicotine
WT x̄ 0.5μM Nicotine
WT x̄ 25μM Nicotine
chrna5-/- 0μM Nicotine
chrna5-/- x̄ 0.5μM Nicotine
chrna5-/- x̄ 25μM Nicotine
b
c
Preference Index
Cliff's delta
n = 30
n = 29
Nicotine Self Administration
d
e
WT
f
chrna5 -/-
Preference index
Entries into stimulus
Time in stimulus
Mean time per stimulus entry
Mean velocity in stimulus
Time in control
0μM
x̄ 25μM
Cliffs Delta
WT 0% Alcohol
WT x̄ 0.125% Alcohol
WT x̄ 0.25% Alcohol
WT x̄ 0.5% Alcohol
chrna5-/- 0% Alcohol
chrna5-/- x̄ 0.125% Alcohol
chrna5-/- x̄ 0.25% Alcohol
chrna5-/- x̄ 0.5% Alcohol
Alcohol Self Administration
g
h
i
n = 30
n = 31
n = 28
n = 29
j
WT
k
chrna5 -/-
0%
x̄ 0.5%

Figure 2. Zebrafish with *chrna5* mutation exhibited reduced aversion to acute nicotine & alcohol exposure by SAZA. (**a**) Schematic of the self administration for zebrafish assay (SAZA) chamber and design. (**b-d, g-i**) Gardener-Altman and Cumming estimation plot dose response curves displaying preference index by relative volume dispensed per fish of (**b-d**) 0-x̄25µM nicotine, or (**g-i**) alcohol, within (**b, g**) WT (greys), (**c, h**) *chrna5* mutant (greens), or (**d,i**) between genotypes. Positive values indicate preference for the stimulus. (**e-f, j-k**) Cliff's delta (± 95% CI) forest plots of all calculated metrics from (**e**, **f**) nicotine and (**j**, **k)** alcohol SAZA, comparing the response of (**e, j**) WT or (**f, k**) c*hrna5* mutants to their baseline behaviour within genotype. Positive values indicate a greater response in the mutant. Asterisks (**b-d, g-i**), or colour (**e-f, j-k**) indicate a significant difference: /blue = p > 0.05 (no significant difference), */purple = p < 0.05 and Cliff's delta > ± 0.2 & < ± 0.4 (provisional difference), **/red = p < 0.01 and Cliff's delta > ± 0.4 (meaningful difference). See tables S4-5 for the precise effect sizes and p-values, corrected for multiple comparisons.

Given the strong links reported between loss-of-function *Chrna5* mutations, or knockouts, and altered intake of nicotine and alcohol in rodent studies [18,21,24], we first characterised if zebrafish *chrna5* mutants also showed similar changes in spite of the evolutionary distance to mammals. To do so, we used the self-administration for zebrafish assay (SAZA) previously reported [40,41] to examine the acute preference to self-administer nicotine and alcohol. Briefly, this assay allowed juvenile zebrafish an uninhibited choice to self-administer a stimulus, conditional on the fish's behaviour of swimming into a dispensing region of the tank (Figure 2(**a**)). In the assay, a three minute pre and a post-stimulus periods were interspersed with an eighteen minute self administration period (Figure 2(**a**)). The parameters, including the volume of stimulus or control dispensed, were collected to calculate the relative preference and absolute behaviour of the animals. The dispensing concentrations of 10/500µM nicotine and 5/10/20% alcohol were diluted to estimated mean concentrations of x̄0.5/x̄25 µM nicotine and x̄0.125/x̄0.25/x̄0.5% alcohol in the stimulus zone, as outlined in Table S2. These terms are used for the remainder of the work.

Wild-type fish (WT) exhibited a strong aversion to nicotine, with increasing magnitude of avoidance correlated with dispensing concentration (Figure 2(**b**) x̄25 µM, Cliff's Delta = -0.762, 95%CI [-0.900, -0.533], $p < 0.01$). However, this aversive response was blunted across the concentrations in *chrna5* mutants, with the preference index of neither the x̄0.5 nor x̄25 µM nicotine differing from the behaviour of the fish when no nicotine (0 µM) was administered (Figure 2(**c**). This resulted in a reduced aversion to nicotine in the mutant that was apparent at both concentrations, with the largest effect observed at x̄25µM nicotine (Figure 2(**d**), x̄25µM, Cliff's Delta = -0.166, 95%CI [-0.488, 0.143], $p = 0.2688$). Overall, these results indicated that the mutation affected the phenotype at higher concentrations of nicotine self-administration, reducing the impact on aversion.

Alcohol also evoked an aversive response in WT fish, albeit to a lesser degree than nicotine, exhibiting a significant change only under the x̄0.5% condition (Figure 2 (**g**) x̄0.5%, Cliff's Delta = -0.611, 95%CI [-0.810, -0.327], $p < 0.01$). When mutant fish were exposed to alcohol, however, both the x̄0.125% and x̄0.25% conditions evoked an attraction (Figure 2 (**h**) x̄0.125%, Cliff's Delta = 0.447, 95%CI [0.121, 0.691], $p = 0.0068$, x̄0.25% Cliff's Delta = 0.444, 95%CI [0.131, 0.665], $p = 0.0018$). In addition, as with nicotine, the response to the aversive x̄0.5% condition was also blunted in the mutants (Figure 2 (**h**) x̄0.5%, Cliff's

Delta = -0.109, 95%CI [-0.181,0.399], p = 0.4654). Again, the inter-genotype comparisons highlighted larger effect sizes and a more defined phenotype at the higher concentrations (Figure 2 (**i** 0.5%, Cliff's Delta = 0.430, 95%CI [0.135,0.667], p = 0.0046). A breakdown of time spent in the stimulus into three-minute windows during the administration period at the highest concentrations of nicotine and alcohol revealed that the behaviour of the mutant fish was driven by a delay in the onset of an aversive response in comparison to the WT (Figure S6). Consistent with the behaviour observed in response to alcohol, the *chrna5* mutants were not tolerant to high concentrations of nicotine either and exhibited an aversion in the later stages of SAZA (Figure S6). The difference between the WT and *chrna5* mutant fish behaviour was negligible in the absence of nicotine or alcohol, indicating that the *chrna5* mutation did not interfere with normal behaviour in the SAZA apparatus (Figure 2(**d, i**). In the presence of either nicotine or alcohol, the evaluation of other behavioural metrics supported the observation of blunted aversion/increased tolerance to these substances (Figure 2 (**e-f, j-k** 25µM nicotine administration conditions, WT fish greatly reduced their time spent in the stimulus zone and number of entries compared to their behaviour in the absence of nicotine, while *chrna5* mutants exhibited no change in these measures (Figure 2 (**e-f** 0.5% alcohol SAZA, WTs reduced their time spent in the stimulus zone and mean time per entry versus baseline, while mutants showed no change (Figure 2 (**j-k**)). In all cases, changes in mean velocity of the fish were observed, a strong indicator for the stimuli delivered in the assay being experienced by the subjects, and altering their preference behaviours (Figure 2 (**j-k**)). Therefore, under these acute exposure parameters, *chrna5* mutants exhibited a phenotype of increased tolerance to substances of abuse, much like those reported in rodents.



Figure 3. Combined multi substance behavioural and transcriptomic analysis schematic detailing **(a)** pre-treatment and self-administration combinations, **(b)** the pre-treatment schemes for alcohol and nicotine repeated daily over seven days, and **(c),** the analyses performed on the pre-treated fish.

We next evaluated the impact of the genetic predisposition on the process of development of substance dependence. To do so, we examined the effect of multi-day exposures on self-administration preference, as substance abuse happens after recurring exposure to these stimuli that alter both gene expression and behaviour [29,49]. Further, nicotine addiction and alcohol abuse are often comorbid in

humans [50,51]. Towards this end, we designed a substance pre-exposure scheme before examining gene expression of the forebrain and midbrain (excluding the olfactory bulb, telencephalon, and hindbrain regions) using bulk RNA-seq and the behavioural response of subject fish in SAZA. Both WT and *chrna5* mutant fish were subjected to a one-week pre-treatment to nicotine or alcohol prior to SAZA, and the SAZA to both substances was conducted following this scheme (Figure 3).


Nicotine Pretreatment
Nicotine Self Administration
SAZA
a WT
b chrna5-/-
c
WT no pretreatment
chrna5-/- no pretreatment
WT nicotine pretreatment
chrna5-/- nicotine pretreatment
Preference index
Entries into stimulus
Time in stimulus
Mean time per stimulus entry
Mean velocity in stimulus
Time in control
0μM
Cliffs Delta
x̄ 25μM
Preference index
Cliffs Delta
n = 30
n = 30
n = 31
n = 30
Alcohol Self Administration
d WT
e chrna5-/-
f
0%
x̄ 0.5%
n = 28
n = 28
n = 29
n = 30
Wild type RNAseq
chrna5-/- RNAseq
No pretreatment
Nicotine pretreatment
PCA (74.43%)
PCA (75.51%)
PC2 (12.4%)
PC3 (9.07%)
PC1 (52.96%)
PC2 (16.08%)
PC3 (10.8%)
PC1 (48.63%)
All genes
Up-regulated
Provisional Up-regulated
Down-regulated
Provisional Down-regulated
Not significant
-log10(P-value)
Acetylcholine
Glutamate
GABA
Dopamine
chrna2b
chrna5
chrna4b
grin2db
grin3ba
GRIN2B
grin2cb
grinaa
grin2da
grin2aa
grin1a
chrnd
chrne
GABRB2
gabra3
gabrb4
gabrg2
gabra1
gabrr2a
gabra4
gabrb2a
GABRR1
gabrz
gabrg1
gabra2a
gabrb3
gabra6b
drd2b
drd2l
drd1b
drd4b
drd2a
drd3
Log2(Fold change)

208 **Figure 4.** Nicotine pre-treatment altered *chrna5* mutant acute behavioural responses to nicotine and
209 alcohol, and effected transcriptomic changes in WT fish. (**a-f**) Measures of fish behaviour in SAZA
210 following a seven day nicotine pre-treatment scheme when self-administering (**a-c**) x̄25μM nicotine or
211 (**d-f**) x̄0.5% alcohol. Comparisons of multiple measures in (**a, d**) WT or (**b, e**) *chrna5* mutants to baseline,
212 or (**c,f**) to each other by preference index, are displayed as forest plots, or Gardener-Altman and
213 Cumming estimation plots, respectively. Asterisks (**c, f**), or colour (**a-b, d-e**) indicate a significant
214 difference: blue = p > 0.05 (no significant difference), */purple = p < 0.05 and Cliff's delta > ± 0.2 & < ±
215 0.4 (provisional difference), **/red = p < 0.01 and Cliff's delta > ± 0.4 (meaningful difference). See table
216 S6 for the precise effect sizes and p-values, corrected for multiple comparisons. (**g-r**) RNA sequencing
217 data of (**g-l**) WT and (**m-r**) *chrna5* mutant fish brain tissues, with the olfactory bulb, telencephalon and
218 hindbrain removed, comparing untreated samples to those collected following a seven day nicotine pre-
219 treatment scheme. (**g,m**) PCA separation of samples. (**h-l, n-r**) Volcano plots of (**h,n**) all genes, (**i,o**)
220 nicotinic acetylcholine receptors (chrn), (**j,p**) glutamate receptors (grin), (**k,q**) GABA receptors (gabr),
221 (**l,r**) dopamine receptors (drd). Significance was categorised as adj $p > 0.05$ = non significant (black), adj p
222 < 0.05, $\log_2$ fold change 0 - ±1 = provisional up (+, orange) or down (-, cyan) regulation, adj $p < 0.05$, $\log_2$
223 fold change ±1 - >±2 = up (+, red) or down (-, blue) regulation.
224
225 Pre-treatment of the WT fish with nicotine appeared to have little impact on their behavioural profile for
226 self-administering nicotine (Figure 4 (**a**), 2(**e**)), or alcohol (Figure 4 (**d**), 2(**j**)). PI, time in stimulus, and
227 number of entries to the stimulus zone all exhibited drastic reductions compared to baseline behaviours
228 (Figure 4 (**a**) PI, Cliff's Delta = -0.792, 95%CI [-0.917,-0.572], $p < 0.01$), as was the case with the non-pre-
229 treated fish (Figure 2 (**e**)). Unlike their untreated counterparts, *chrna5* mutants however, exhibited a
230 small but significant negative shift in preference index and time spent in stimulus in the x̄25μM nicotine
231 SAZA following nicotine pre-treatment (Figure 4 (**b**) PI, Cliff's Delta = -0.414, 95%CI [-0.667, -0.0989], p =
232 0.0058), suggesting a reduced tolerance compared to the untreated phenotype (Figure 2 (**f**)). This
233 narrowed the phenotypic gap between the two genotypes slightly (Figure 4 (**c**) pre-treated mutant vs
234 WT, Cliff's Delta = 0.338, 95%CI [0.0258, 0.578], p = 0.0244), though whether this was due to a true lack
235 of change in phenotype in the WT fish, or if the lower bounds to quantify avoidance behaviours in the
236 SAZA had already been reached, require additional lines of experimentation.
237 Unlike in nicotine self-administration, the behavioural profile of WT fish to self-administering alcohol in
238 the SAZA assay indicated reduced aversion following nicotine pre-treatment, compared to their
239 untreated counterparts (Figure 4 (**d**) PI, Cliff's Delta = -0.383, 95%CI [-0.637, -0.0713], p = 0.011). The
240 *chrna5* mutant fish also exhibited a higher preference for x̄0.5% alcohol following nicotine pre-
241 treatment (Figure 4 (**e**) PI, Cliff's Delta = 0.335, 95%CI [0.0516, 0.587], p = 0.0252). This is in contrast to
242 the response of untreated mutants, which displayed a neutral preference (Figure 2 (**k**)). This suggests
243 that nicotine pre-treatment amplified the alcohol tolerance phenotype previously observed for the
244 mutants and WT alike. Next, we performed bulk RNA-sequencing on the midbrains of fish that had
245 undergone the nicotine pre-treatment to get a deeper understanding of potential causes for these
246 behavioural shifts from the transcriptomes. While untreated and pre-treated samples were separated in
247 the PCA for both genotypes (Figure 4 (**g, m**)), nicotine pre-treatment of c*hrna5* mutants appeared to
248 effect fewer transcriptomic changes than in WT in the dissected brain regions (Figure 4 (**h, n**)). Nicotinic

249 acetylcholine receptor subunit expression was unchanged after the pre-treatment in either genotype
250 (Figure 4 (**i, o**). Interestingly, several genes in the glutamate, GABA, and dopamine receptor families
251 were significantly downregulated only in the WT fish (Figure 4 (**j-l, p-r**)) that were unaltered in the
252 mutants. Untreated WT and *chrna5* mutant fish showed few transcriptomic differences (Figures S8-9).


Alcohol Pretreatment
Alcohol Self Administration
SAZA
a WT
b chrna5-/-
c
WT no pretreatment
chrna5-/- no pretreatment
WT alcohol pretreatment
chrna5-/- alcohol pretreatment
Preference index
Entries into stimulus
Time in stimulus
Mean time per stimulus entry
Mean velocity in stimulus
Time in control
Cliffs Delta
Nicotine Self Administration
d WT
e chrna5-/-
f
0μM
25μM
Wild type RNAseq
chrna5-/- RNAseq
No pretreatment
Nicotine pretreatment
PCA (71.48%)
PCA (71.5%)
PC1 (42.07%)
PC2 (19.29%)
PC3 (10.12%)
PC1 (44.64%)
PC2 (18.81%)
PC3 (11.05%)
All genes
-log10(P-value)
Acetylcholine
Glutamate
GABA
Dopamine
chrna4b
grin1a
gabrb2a
log2(Fold change)

254 **Figure 5.** Alcohol pre-treatment abolished *chrna5* mutant nicotine tolerance phenotype, and stimulated
255 upregulation of WT nicotinic acetylcholine receptor genes (**a-f**) Measures of fish behaviour in SAZA
256 following a seven day alcohol pre-treatment scheme when self-administering (**a-c**) x̄0.5% alcohol or (**d-f**)
257 x̄25μM nicotine. Comparisons of multiple measures in (**a, d**) WT or (**b, e**) *chrna5* mutants to baseline, or
258 (**c, f**) to each other by preference index, are displayed as forest plots, or Gardener-Altman and Cumming
259 estimation plots, respectively. Asterisks (**c, f**), or colour (**a-b, d-e**) indicate a significant difference: blue =
260 p > 0.05 (no significant difference), */purple = p < 0.05 and Cliff's delta > ± 0.2 & < ± 0.4 (provisional
261 difference), **/red = p < 0.01 and Cliff's delta > ± 0.4 (meaningful difference). See table S7 for the
262 precise effect sizes and p-values, corrected for multiple comparisons. (**g-r**) RNA sequencing data of (**g-l**)
263 WT and (**m-r**) *chrna5* mutant fish midbrain tissues comparing untreated samples to those collected
264 following a seven day alcohol pre-treatment scheme. (**g, m**) PCA separation of samples. (**h-l, n-r**)
265 Volcano plots of (**h, n**) all genes, (**i, o**) nicotinic acetylcholine receptors (chrn), (**j,p**) glutamate receptors
266 (grin), (**k, q**) GABA receptors (gabr), (**l, r**) dopamine receptors (drd). Significance was categorised as adj
267 $p > 0.05$ = non significant (black), adj $p < 0.05$, $\log_2$ fold change 0 - ±1 = provisional up (+, orange) or
268 down (-, cyan) regulation, adj $p < 0.05$, $\log_2$ fold change ±1 - >±2 = up (+, red) or down (-, blue)
269 regulation.
270
271 We next examined the self-administration behaviour of fish pre-treated with alcohol. Similar to the
272 nicotine pre-treatment results, there was no observable impact on the self-administration behaviours of
273 WT fish. WT fish continued to avoid x̄0.5% alcohol (Figure 5 (**a**) PI, Cliff's Delta = -0.617, 95%CI [-0.799, -
274 0.347], $p < 0$), similar to the strong aversion seen without pre-treatment (Figure 2 (**j**)). Mutants, in this
275 case, were unchanged in their behavioural measures to alcohol self-administration and resembled
276 untreated mutant fish (Figure 5 (**b**), 2(**k**)). The only notable difference between the alcohol pre-treated
277 and untreated fish being time per entry (Figure 5 (**b**) mean time per entry, Cliff's Delta = 0.5, 95%CI
278 [0.181, 0.739], $p = 0.004$). Inter genotype comparison, however, revealed that the difference observed
279 between untreated WT and mutants had been abolished following the alcohol pre-treatment (Figure 5
280 (**c**) WT vs mutant pre-treated, Cliff's Delta = 0.225, 95%CI [-0.0927, 0.504], $p = 0.1302$). This appeared to
281 be due to an increase in variance amongst the assayed mutant population, which exhibited a more polar
282 distribution.
283 Finally, we examined the effects of cross treatment on self administration here as well. Alcohol pre-
284 treated fish were given the choice to self administered x̄25μM nicotine. WT fish in this condition showed
285 aversive behaviour broadly similar to their untreated counterparts (Figure 5 (**d**)). The *chrna5* mutants
286 were examined next. Here too, as was the case with the nicotine pre-treated fish, alcohol pre-treatment
287 appeared to reduce the tolerance of mutants to nicotine. Nicotine self-administration across multiple
288 measures, including PI changed towards avoidance (Figure 5 (**e**) PI, Cliff's Delta = -0.502, 95%CI [-0.731,-
289 0.182], $p < 0$). This increase in aversive behaviours resulted in a narrowing of phenotypic differences
290 originally seen between the genotypes. The PI difference was no longer significant (Figure 5 (**f**) WT vs
291 mutant pre-treated, Cliff's Delta = 0.260, 95%CI [-0.0603, 0.527], $p < 0$). RNA sequencing of the
292 midbrains of the alcohol pre-treated fish revealed a phenomenon parallel to that observed after
293 nicotine pre-treatment. The pre-treated and untreated samples of each genotype were separated by
294 PCA (Figure 5 (**g, m**)), but again the scale of transcriptomic changes in the *chrna5* mutants amongst all

295 genes was sharply lower than the transcriptome changes in the WT (Figure 5 (**h, n**)). Curiously, the
296 pattern of expression changes amongst the neurotransmitter systems was almost the complete inverse
297 of that observed after nicotine pre-treatment. Alcohol pre-treatment stimulated strong upregulation
298 amongst many nicotinic acetylcholine receptor subunits (Figure 5 (**i**)), but little change was observed in
299 the glutamate, GABA, and dopamine receptors that were downregulated after nicotine pre-treatment.
300 Once again, *chrna5* mutants exhibited little alteration to the transcriptomic profiles of these receptor
301 genes (Figure 5 (**o-r**)). Thus, although pre-treatment with nicotine or alcohol had no notable population
302 level change in the self-administration behaviours of WT fish, it resulted in large scale gene expression
303 changes within the dissected brain regions. On the other hand, the behaviour of the mutant *chrna5* fish
304 changed with limited changes in transcriptional profiles of the midbrain.


Light/Dark Anxiety Assay
Circadian Rhythm Assay
Feeding and Appetite Assay
Dorsal view
Visible light source
Dark
Light
Opaque cylinder
Infrared LED
Opaque container
WT
chrna5-/-
Time Spent in the dark (%)
Number of Entries to dark Side
First entry to dark
Cumulative Percentage (%)
Time (seconds)
Cliff's delta
Tracking
Infrared LED
Speaker
Opaque container
Visible light source
Tracking
Light/Dark transition assay
Vibration assay
START
END
Time inactive (m)
Cumulative pixels travelled + 95% CI
Vibration intensity (%)
Mean locomotor activity (mm ± 95% CI)
Time (m)
Light -> Dark transition (0m)
Dark -> light transition (30m)
Egg Yolk
Protein
Paramecia
Mean fluorescence intensity
7 dpf - Pre-feeding
Unlabelled food
Wash
7 dpf - Final feed
DiD labelled food
Overnight
Quantify gut fluorescence

305

306 **Figure 6.** Appetite and circadian rhythm disorder associated phenotypes were altered in *chrna5*
307 mutants. **(a-d).** Anxiety-like behaviour of 12-14 dpf larvae in light/dark assay. **(a)** Schematic of the
308 light/dark assay equipment. Chambers were illuminated from below, divided into equal light and dark
309 halves, and movement between the areas was tracked. **(b-d)** Behavioural measures of **(b)** time spent in
310 dark, **(c)** number of entries to dark, and **(d)** cumulative first entry time of the population to the dark over
311 the assay duration between WT and *chrna5* mutant fish. **(e-l)** Circadian rhythm, vibration sensitivity, and
312 light-dark transition behaviours of 7-10 dpf fish. **(e)** Schematic of the circadian assay equipment and
313 tracking (upper), and the assay timeline (lower). Yellow indicates visible lights are on, while black is off.
314 **(f-h)** Time inactive over assay duration, divided according to light on/off times in **(f)** WT, **(g)** c*hrna5*
315 mutants, and **(h)**, between genotypes. **(i)** Mean cumulative distance moved by fish per vibration
316 stimulus intensity between genotypes. **(j-l)** Light-dark transition locomotor response. **(j)** Mean
317 locomotor activity across all five cycles between genotypes. Yellow/grey areas indicate visible light on
318 and off, respectively. **(k-l)** Difference in individual locomotor activity within and between genotypes
319 (delta-delta) from before and after **(k)** light to dark transition at 0 minutes, and **(l)** dark to light transition
320 at 30 minutes. **(m-p)** Feeding behaviour of 7-dpf fish given assorted food types. **(m)** Schematic detailing
321 feeding protocol, pre-feeding, and starvation periods prior to the labelled feed. **(n-p)** Mean fluorescent
322 intensity gut intensity of WT and *chrna5* mutant fish when fed **(n)** egg yolk, **(o)** protein, and **(p)**
323 *paramecia*. * = $p < 0.05$ and Cliff's Delta from ±0.2 to ±0.4 (where applicable), ** = $p < 0.01$ and Cliff's
324 Delta from > ±0.4 (where applicable). See tables S8-9 for the precise effect sizes and p-values, corrected
325 for multiple comparisons.
326
327 Nicotine dependence is frequently comorbid with a variety of disorders, including increased anxiety,
328 alteration in circadian rhythms, and appetite dysregulation in humans [52–54]. While specific variants in
329 the CHRNA5-CHRNA3-CHRNB4 gene cluster, particularly the CHRNA5 variant rs16969968, are strongly
330 associated with nicotine dependence [55,56], a direct link between CHRNA5 and comorbid disorders
331 more tentative [57]. However, a genetic predisposition for comorbid disorders is proposed [20]. Given
332 that our *chrna5* mutant zebrafish exhibited a tolerance phenotype towards nicotine and alcohol that
333 could act as a pathway to dependence, we evaluated if the mutation impacts any other behaviours in
334 the fish. Nicotine and alcohol are both described as drugs that can have an anxiety reducing effect at
335 specific doses in both humans and zebrafish [58–61]. As such, the drive to ameliorate anxiety is cited as
336 a potential cause for the use of these psychoactive drugs. Whether genetic predisposition to developing
337 drug dependence also causes individuals to have an anxiety phenotype due to a gene mutation or
338 variant is debated [20]. To determine if *chrna5* mutant zebrafish also exhibit higher anxiety-like
339 behaviours, we used a light/dark assay. 12-14 dpf zebrafish naturally exhibit scotophobia, or dark
340 avoidance behaviours [62]. The behaviour of fish that were allowed to swim uninhibited between two
341 zones, one illuminated and one darkened, was quantified (Figure 6 (**a**)). Individuals spending more time
342 in the dark, entering the dark sooner or more frequently, are all representative of a state of reduced
343 anxiety-like behaviour in larval zebrafish. Both WT and mutant fish spent more time in the illuminated
344 areas and entered the darkened area only after a few minutes. In all of these measures (Figure 6 (**b-d**),
345 S7) no significant difference was observable between the WT and *chrna5* mutants. Thus, *chrna5* had
346 little to no direct involvement in governing anxiety-like phenotypes in fish.

347 Nicotine, along with other substances of abuse, has also been implicated in the disruption of sleep and
348 circadian rhythms both directly in animal models, and by comorbidity in human genetic studies [63–66].
349 However, despite the nicotinic acetylcholine receptor family being involved in the maintenance of
350 circadian rhythms and the sleep-wake cycle [67], whether *chrna5* plays a role is untested. To study the
351 circadian rhythm, we tracked the activity of 7-10dpf larval zebrafish over 24 hours, starting in the
352 afternoon (Figure 6 (**e**)). Over a period of 24 hours, the light and dark periods were maintained to the
353 entrained day-night cycle experienced by the larvae prior to the assay. Intermittent light-dark switches
354 and vibrational stimuli were administered to challenge the animals and record their behaviours to
355 disturbance. Both the WT and *chrna5* mutants maintained normal diurnal circadian rhythms, exhibiting
356 lowest activity at night (Figure 6 (**f**) Cliff's Delta = 0.514, 95%CI [0.284,0.690], $p<0.001$, Figure 6 (**g**) Cliff's
357 Delta = 0.840, 95%CI [0.699,0.922], $p<0.001$) and highest in the morning (Figure 6 (**f**) Cliff's Delta = -
358 0.797, 95%CI [-0.894,-0.635], $p<0.001$), Figure 6 (**g**) Cliff's Delta = -0.703, 95%CI [-0.834, -0.514], $p<0.001$.
359 However, the mutant fish displayed lower overall activity during each time period, with the greatest
360 difference between the genotypes occurring during the night (Figure 6 (**h**)). Conversely, during the
361 nocturnal vibration tests, *chrna5* mutants exhibited greater motility, suggesting increased sensitivity to
362 physical stimuli (Figure 6 (**i**)). During the light-dark transition period of the assay, both genotypes
363 exhibited a locomotor response to both the "dark flash" (light to dark), and the "light flash", that is dark
364 to light transition. However, the WT fish response peaked considerably higher than the mutants when
365 the light was turned off, and maintained greater activity until the light was switched back on (Figure 6 (**j-**
366 **k**)). The WT also showed a stronger response to a dark-light transition, but in this case, exhibited
367 reduced locomotion following the light being switched on (Figure 6 (**j, l**)).

368 The link between nicotine consumption and feeding behaviour is well documented, with nicotine
369 administration being associated with reduced body weight and a decrease in consumption of calorie
370 dense foods [68,69]. Nicotine is thought to both alter the balance of orexigenic and anorexigenic
371 peptides to change homeostatic feeding, while also exerting influence over dopamine release which
372 modulates hedonistic feeding behaviours [70]. In addition, the CHRNA5-CHRNA3-CHRNB4 gene cluster is
373 expressed in the arcuate nucleus of the hypothalamus (ARC) which can impact appetite directly [71,72].
374 Global Chrna5 receptor knockout in rodents changes preference for some food rewards, but not all [73].
375 To evaluate this further, we examined consumption of three types of food: a fat rich chicken egg yolk, a
376 customised protein rich feed, and live *Paramecium caudatum*, a natural prey item of larval zebrafish in
377 an appetite assay [38]. The assay quantified feeding by fluorescent labelling of the feed and subsequent
378 quantification of the fluorescent signal from the gut following the feeding period (Figure 6 (**m**)). Swarm
379 Plots of the quantity of feed consumed by zebrafish across 10 repetitions of the assay for each food type
380 revealed that the *chrna5* mutants tended to eat less fat-rich egg yolk than the WT (Figure 6 (**n**) Cliff's
381 Delta = -0.203, 95%CI [-0.109, -0.296], $p<0.001$), but, more protein (Figure 6 (**o**) Cliff's delta = 0.312,
382 95%CI [0.218, 0.404], $p < 0.001$) and *Paramecium* (Figure 6 (**p**) Cliff's delta = 0.18, 95%CI [0.088, 0.274], p
383 $= < 0.001$). Therefore, similar to the observations in rodents, *chrna5* mutants show an increased appetite
384 for palatable food reward.

385 Overall, the behaviour of *chrna5* mutants differed from the WT in some phenotypes associated with
386 human disorders often comorbid with substance dependence, such as appetite and circadian regulation.

387

Discussion

Here, we generated a global *chrna5* zebrafish mutant to study the neurobehavioural consequences of dysfunction in a genetic factor associated with several frequently comorbid human disorders. *chrna5* mutants exhibited heightened tolerance to acute nicotine self-administration, a phenotype also observed in loss-of-function rodents [18,21]. This suggests that dysfunctional *chrna5* impacts tolerance to nicotine across vertebrates, and may similarly affect humans with reduced *CHRNA5* function. Notably, Genome Wide Association Studies (GWAS) have independently linked polymorphisms in the *CHRNA5–CHRNA3-CHRNB4* gene cluster to alcohol dependence [22]. Rodent studies exploring this association have yielded mixed results, with transgenic rodents expressing human *CHRNA5* polymorphism exhibiting behaviors similar to human phenotypes [26,74], but *Chrna5* knockout mice show an impact on alcohol consumption only at certain concetrations [24,25]. In contrast, zebrafish *chrna5* mutants showed an increased tolerance to both nicotine and alcohol self-administration. Therefore, the natural phenotype of zebrafish mutants aligns more closely with human GWAS.

Development of substance dependence is a multigenic, multiphasic, and multi-level phenomenon. Although our experiments of multiday nicotine or alcohol pre-treatments are relatively short, our investigation of the midbrain transcriptomics alongside acute self-administration in juvenile fish is particularly relevant in the context of Adolescent Brain Cognitive Development studies (ABCD [9,10,75]). Chronic nicotine exposure over weeks is known to desensitise nicotinic acetylcholine receptors [29,76], and influence reinforcement behaviours mediated by dopaminergic circuits [77]. Most rodent studies report that such exposure reduces inhibitory control and drug aversion, resulting in higher nicotine intake even after only a brief preexposure [28,78]. However, social suppression in nicotine self-administration has also been observed [79], and environmental enrichment and social housing conditions can reduce alcohol self-administration [80,81]. Thus, examining how genetic factors modulate these behaviours in the zebrafish - a shoaling, social species offers valuable comparative insights.

Our data showed that juvenile WT fish exhibited broad transcriptomic changes in both excitatory (glutamatergic) and inhibitory (GABAergic) neurotransmitter receptor systems following nicotine pre-treatment (Figure 4 (**j-l**)). These changes likely maintain equilibrium across reward and aversion circuits, as indicated by the nicotine self-administration profiles of pre-treated and untreated groups (Figure 4 (**a**)). The transcriptomic changes seen in the WT parallel findings in adult rodents where modulation of dopamine receptors drd1 and drd3 [82,83], or NMDA receptors (grin) grin1-3 [84,85]) reduces intravenous nicotine self-administration. Unlike our expectations, however, nAChR gene expression changes were minimal (Figure 4 (**i**)) with upregulation of α4 as the only exception, which may influence the dopaminergic neural function [86]. In contrast, the differential gene expression profile of the *chrna5* mutants changed minimally after nicotine pre-exposure, while their behaviour shifted towards aversion (Figure 4). These results suggest that reward and aversion to nicotine may be finely tuned by the same genetic players across vertebrates.

Unlike nicotine pre-treatment, alcohol pre-treatment induced large changes in cholinergic receptor expression in the WT fish, with small or no change in dopaminergic, GABAergic, and glutamatergic receptor gene expression. Changes were seen in non-neural genes (*chrna1, chrne, chrnd,* and *chrng [87,88]*) as well as neuronal *chrna6* and *chrna9,* both associated with nicotine [89,90] and alcohol

429 [87,91] dependence in humans. The upregulation of GABRA6 in WT fish was interesting to note, as
430 human variants in the gene are known to reduce sedation, though the effects on acute self-
431 administration are unknown [92,93]. Once again, *chrna5* mutants showed a limited gene expression
432 profile change in comparison to the WT, and showed the strongest behavioural shift, to nicotine self-
433 administration (Figure 5 (**d-f**)). In addition, increased variance exhibited by *chrna5* mutants (Figure 5 (**c**))
434 suggested influence over inter-individual response variability. Thus, alcohol pre-treatment induced
435 compensatory gene expression changes in WT that were absent in the mutants. Together, these
436 observations suggest an inverse relationship between transcriptomic changes and behavioural
437 responses after preexposure to psychoactive substances like nicotine and alcohol for short periods.
438 Whether longer term exposure maintains these differences and direction of change is a topic of further
439 research. If the WT transcriptome reflects homeostatic changes, compensating for circuit functionality,
440 then mutants lacked this protective response. If this mechanism is conserved across vertebrates,
441 *CHRNA5* variants that reduce the function of CHRNA5 in humans could suppress compensatory
442 biochemical changes, amplifying the direct impacts of nicotine or alcohol.

443 Nicotine and alcohol comorbidity is well documented in humans [50,51], and at a molecular level in
444 animals [94], making the effects of cross treatments particularly interesting. While rodent studies
445 commonly report that drug pre-exposure increases subsequent intake [28,49] we only observed this for
446 nicotine pre-treatment followed by alcohol self-administration. Nicotine pre-treatment shifted both
447 genotypes towards alcohol attraction, suggesting that the transcriptional changes induced by one
448 substance can influence tolerance or another (Figure 4 (**d, e**)). In addition to technical differences
449 between species, these findings may indicate the impact on the developing brains of juvenile fish.
450 Furthermore, many genes exhibiting altered expression in the WT were linked to addiction, withdrawal,
451 and relapse, highlighting the bidirectional nature. These included D2 and D4 receptors, which exert
452 influence on withdrawal symptoms, place preference, and relapse to nicotine seeking behaviour but not
453 acute nicotine response [95–97], and have human variants associated with nicotine and alcohol use
454 [98,99]. Interestingly, D4 was also differentially expressed prior to pre-treatments (Figure S8, S9), while
455 D3 (drd3) known to affect alcohol consumption in rodents [100], was one of the few genes with
456 expression altered to a similar degree in both genotypes by nicotine pre-treatment. Additionally,
457 GABRA2 and GABRA4 have several nicotine dependence associated SNPs [101], while GABRR1 and
458 GABRR2 SNPs have been associated with alcohol dependence [102]. Finally, *GRIN2A* is associated with
459 heroin addiction in GWAS [103]. These observations suggest that zebrafish can provide new insights into
460 understanding the initial phases of substance dependence in young brains.

461 Mutations in *CHRNA5* are associated with vulnerability to anxiety, albeit only under certain conditions
462 [57,74]. Mutant zebrafish displayed no altered anxiety phenotype in the light/dark assay (Figure 6 (**b-d**)),
463 thus more closely matching human GWAS studies than rodent studies. CHRNA5's role in nicotine use
464 disorders may thus develop independently of an anxiety phenotype. Increased tolerance, in turn, could
465 influence an increased rate of smoking. As anxiety phenotypes can vary in their manifestations and
466 differ between social and asocial settings, additional studies examining other anxiogenic conditions will
467 be needed to further evaluate if the dissociation manifests in other contexts.

468 The link between nicotine consumption and circadian rhythms is also well known [63–66]. More recent
469 investigations are beginning to uncover the bidirectional influence of genetic variation on both [66]. The

diurnal activity cycle of the *chrna5* fish mutants was similar to the WT, even if their activity was lower at various stages within it, especially at night (Figure 6 (**f-h**)). This suggests a potential role for *chrna5* in sleep quality, independently of nicotine or alcohol consumption. Additionally, the visuomotor response (VMR) to dark flashes and dark-light transitions [104] was weaker in *chrna5* mutants. As low levels of expression could be seen in the preoptic, hypothalamic, and pineal gland circuits that are proposed to influence these responses [105,106], it implies that *chrna5* may have a direct role. It is also possible that *chrna5* function is more relevant in the distributed learning circuits associated with dark flash habituation [107].

Finally, nAChR receptors have been previously implicated in the control of feeding and appetite [71,72]. Our results suggest that *chrna5* exerts some influence over appetite, independent of nicotine administration, as evidenced by the altered consumption by mutants (Figure 6 (**n-p**)). However, the direction of change was dependent on food type - mutants consumed less egg yolk, but more of a protein-rich diet, and *Paramecium caudata*. Among these, paramecia require prey hunting behaviour and coordinated locomotion making it more challenging compared to passive feed like protein-rich and egg yolk powder [108]. Notably, reduced locomotion seen in the circadian rhythm assay (Figure 6 (**h**)) did not impact the *chrna5* mutants to outperform WT larvae in hunting. As the effect sizes were small in these assays, *chrna5* may contribute only minimally to appetite regulation. In rodents, *Chrna5* was amongst the lowest abundance nAChR subunits in the hypothalamic arcuate nucleus, and did not form functional receptors with β4, a known mediator of nicotine induced appetite reduction [109]. Since these feed types differ dramatically in form, nutritional quality, and motility further studies are necessary to understand what among macronutrient content, visual cues, or hunting drives mutant behaviour [110].

Conclusion

This whole-body *chrna5* mutant zebrafish exhibits aligned phenotypes with human conditions, making it a valuable and practical model for investigating the neurobiological basis of development of substance use disorders (SUD). Short term pre-exposure to multiple substances revealed novel cross-substance effects on nicotine and alcohol self-administration in these mutants, highlighting the impact of prior substance exposure on subsequent drug use behavior. Parallel transcriptomics showed altered expression of dependence associated genes in wild type fish that were absent in mutants, suggesting a disruption to homeostatic responses. Together, our results suggest that disruption of *chrna5* increases susceptibility to substance dependence, impairs adaptive responses, and affects behaviours such as appetite and circadian rhythms, which are frequently altered in humans in the context of SUD.

Materials & Methods

Fish husbandry

Zebrafish (*D. rerio*, ABWT) were housed, bred, and reared at the ZebraFish Facility (Institute of Molecular and Cell Biology, A*STAR) in groups of 20–30 in 3 L tanks at 28°C. Fish were kept under a 14:10 light dark cycle and fed as per standard operating procedures of ZFF. All experimental protocols

509 involving zebrafish were approved by the Institutional Animal Care and Use Committee (IACUC) of the
510 Biological Resource Center at A*STAR. Approved experimental protocols (IACUC #201529, #231808,
511 #231797) were followed.

512 Generation of *chrna5* mutant zebrafish

513 Zebrafish gene editing by CRISPR-Cas9 is comprehensively described by Hwang *et al. [111]*. In brief,
514 CRISPR targets for *chrna5* were determined using the web tool 'chop-chop' for the exon 8, targeting
515 between the 3rd and 4th transmembrane helices to disrupt key functional domains. Primers for
516 generating sgRNA are detailed in Table 1. Zebrafish embryos (nacre background) were injected at the 1-
517 cell stage with 1 nL of a mixture containing 1 µL sgRNA (≈ 4-5 µg) and 1 µL Cas9 mRNA (≈1 µg). Fish were
518 genotyped by fin-clipping and sequencing of genomic DNA at 10 weeks post-injection to identify founder
519 fish (F0). The identified founder fish were outcrossed to AB background WT fish to obtain F1 embryos.
520 F1 embryos from each outcrossed family were collected and some of the embryos were genotyped.
521 Once germline transmission was confirmed, the remaining embryos were grown to adulthood.
522 Homozygous *chrna5* mutants from the F3 generation onwards were used for all subsequent
523 experiments, henceforth referred to as *chrna5*$^{-/-}$.
524
525 Table 1. Primers for single-guide RNA template. CRISPR targets are underlined

Gene	Label	Primer 5' ⇒ 3'
chrna5	CRISPR Forward	AATTAATACGACTCACTATAGG<u>GTAGCGAGGAGAAGG</u>GTTTTAGAGCTAGAAATAG
Universal Primer	CRISPR Reverse	TTTTGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAAC

526 Self-administration for zebrafish assay (SAZA) apparatus setup

527 Full descriptions of the tanks and apparatus used for the SAZA assay can be found in [40] and [41]. In
528 brief, the assay tanks were constructed of 3mm thick opaque acrylic (dimensions: 35 x 75 x 30mm,
529 width × length × height). One narrow end of the tank was divided by a sheet of the same material,
530 30mm in length, to split that end into two halves, while still permitting access by the fish (Figure 2 (**a**)).
531 The tank was placed on top of an LED lightbox, providing 5000 lux at maximum intensity (LightPad LX
532 Series, Artograph, USA). Videos were captured at 30 frames per second using an acA2040-90µM USB3.0
533 Basler camera. Nicotine, alcohol and control solutions were dispensed by gravity from 10ml syringes,
534 mounted vertically an equal distance above the tank, through silicon tubing (outer diameter: 1/16",
535 inner diameter 1/32") into the corner of their designated zone. Dispensing was mediated via solenoid
536 pinch valves, set to open only when a tracked fish entered the designated zone (Automate Scientific,
537 USA, SKU: 02-pp-04i) (Figure 2 (**a**)). Fresh system water was consistently supplied to the tank via
538 additional silicon tubing at the opposite end of the tank to the stimulus/control delivery zones. Water
539 was also removed from the tank at a matching rate (~2ml per minute) by gravitational siphoning, with
540 the outflow tubing positioned at the end of the dividing sheet, outside the stimulus/control delivery

541 zones (Figure 2 (**a**)). This created a constant gentle flow of water through the tank, while also preventing
542 the dispensed solutions from escaping their designated zones (Figure 2 (**a**)). Custom LABVIEW software,
543 CRITTA (http://www.critta.org), was used to track fish movements as described by Krishnan *et al.* (2014)
544 [112].

545 ## SAZA

546 The SAZA assay was performed as described by [40] and [41]. Each tank was filled with 40 ml of system
547 water, with the system water inflow and outflow tubes, and the stimulus and control dispensing tubes,
548 inserted into their respective positions. Juvenile zebrafish (30-35 dpf), naive to SAZA, were taken from
549 the husbandry tanks, and one was added to each SAZA tank while minimising disturbance. Each fish was
550 given approximately five minutes to adjust and recover post-transfer, until consistent swimming
551 behaviour had resumed and the fish had explored all zones of the SAZA tank. Fish that did not exhibit
552 consistent swimming behaviour after the recovery period were removed from the tank and replaced
553 with a new fish. The recording and tracking scheme was then started, lasting for 24 minutes and
554 consisting of three consecutive periods; three minutes of pre-exposure, 18 minutes of self-
555 administration stimulus delivery, and three minutes post-exposure. Only during the 18-minute stimulus
556 delivery period would entry to a designated stimulus/control zone trigger dispensing of the
557 corresponding solution (Figure 2 (**a**)). The stimuli delivered were 0/5/10/20% of absolute alcohol, or
558 0/10/500µM nicotine hydrogen tartrate salt (cat #6019-06-3 Sigma) diluted in system water. These
559 source concentrations were diluted in the stimulus zone, with the concentration increasing over time
560 with repeated fish entries, estimated from ~40x to 10x dilution with nicotine, and measured at ~70x to
561 ~30x with alcohol. This resulted in mean stimulus chamber concentrations during SAZA of x̄0.5/x̄25 µM
562 nicotine and x̄0.125/x̄0.25/x̄0.5% alcohol, respectively, as outlined in Table S2. These terms were used
563 for the remainder of the work. Following each assay, the tank was emptied of all liquid, rinsed, and
564 refilled before adding the next fish to prevent contamination of the subsequent assay. The volume of
565 each solution dispensed by each fish was recorded. Periodically throughout the experiment, the zone
566 designated to deliver the stimulus solution was randomly assigned to be either the left or right, and
567 changed such that ~50% of the fish were tested in each configuration in order to reduce bias.
568 Approximately 30 fish were assayed per concentration of alcohol or nicotine. Following each assay, the
569 fish were euthanized. In some cases, zebrafish were pre-treated with exposure to alcohol or nicotine
570 solutions before being assayed. For these assays, each fish was immersed in either 1µM nicotine or 1%
571 alcohol, diluted in system water, for one hour for seven consecutive days. Following this pre-treatment,
572 these fish were returned back to the facility for usual husbandry. On the eighth day, the fish were
573 subjected to SAZA, either using the same substance as introduced during pre-treatment, or the
574 opposite, creating four total conditions (Figure 3 (**a**)).

575 ## SAZA Data analysis

576 CRITTA tracking data from SAZA were processed by custom Python scripts. These provided data on time
577 spent in each zone, mean velocity in each zone, number of entries, and mean time per entry used in
578 these analyses. The data were separated into three major time groups; pre-exposure, total stimulus
579 delivery period, and post-exposure. The stimulus delivery period was also subdivided into three minute

580 segments (0-3m/3-6m/6-9m, and so forth) for some further analyses. The preference index was
581 calculated for the total stimulus delivery period, based on the volume of each solution dispensed, by the
582 following formula; PI = (VolS - VolC) / (VolS + VolC), where VolS = volume dispensed in stimulus zone (ml)
583 and VolC = volume dispensed in control zone (s). This gives the value for PI a maximum range of + or - 1
584 indicating more volume dispensed, relative to the total, in the stimulus or control, respectively. For
585 example, a PI of +1 would indicate 100% of the total volume dispensed was in the stimulus zone during
586 the assay, while a PI of 0 would indicate equal volumes were dispensed in each zone.

587 ## RNA extraction

588 Six-month old adult zebrafish were euthanized, and the brains were dissected in 1x PBS pH 7.0, selecting
589 the forebrain and midbrain regions (excluding the olfactory bulb, telencephalon, and hindbrain regions).
590 Brain tissue was homogenised using a micro tube homogenizer (Thomas Scientific) in a Trizol lysis buffer
591 (ThermoFisher #15596026). RNA was then extracted using PureLink® Micro Kit (ThermoFisher
592 #K310250) according to the manufacturer's protocol. The concentration and purity of the extracted RNA
593 were determined by NanoDrop™2000 Spectrophotometer (ThermoFisher). Each brain sample yielded
594 around 100 ng/µL RNA with a ratio of absorbance reading 1.9-2.0 at 260/280 nm. Some RNA samples
595 were sent for bulk sequencing, detailed below. The remaining purified RNA was reverse transcribed by
596 SuperScript II First strand Synthesis System (Invitrogen #18091050) using 100 ng/µL of purified RNA to
597 obtain approximately 1000 ng/µL of first strand cDNA. Negative controls containing no reverse
598 transcriptase were set up for each sample to check for genomic DNA contamination. The cDNA was
599 diluted with nuclease-free water to 100 ng/µL and used for qRT-PCR.

600 ## RNAseq

601 The quality of each RNA sample was verified before sequencing by gel electrophoresis and bio-analyser.
602 Samples that passed QC were sent for sequencing by BGI. An mRNA cDNA library made up of paired-
603 end sequencing reads of 150 bp in length was generated on the Illumina HiSeq instrument. Raw reads
604 were first processed to remove adapters, poly-N sequences, and reads with low quality from the raw
605 data. All downstream analyses were based on the clean data with a Phred score of 39, indicating a
606 99.9% base call accuracy. Further analysis was performed in Partek™ Flow™ Explore Spatial Multiomics
607 Data using Partek™ Flow™ software, v11.0. Reads were aligned to GRCz11 genome assembly by STAR
608 aligner, default parameters, and subsequently filtered to a minimum mapping quality score of > 30.
609 Gene counts were normalised by median ratio, followed by differential expression analysis in DeSeq2.
610 Significance thresholds were set as follows: up/down-regulated genes = $p < 0.05$ & fold change > ±2.
611 Provisional up/down-regulated genes = $p < 0.05$ & fold change < ±2. Non-significant genes = $p > 0.05$.
612 Custom gene lists and sets for analysis can be found in Table S10. Gene set enrichment analysis (GSEA)
613 was performed using the GRCz11-GO database, 100 permutations. Significance thresholds were set at p
614 < 0.05 and FDR < 0.25.

615 qRT-PCR

616 The qRT-PCR amplification mixtures (20 µL) contained 100 ng of cDNA, 10 µL 2x GoTaq®qPCR Master
617 Mix (Promega #TM318), and 300 nM forward and reverse primers. The primers used were designed
618 using Primer3 (v.0.4.0) and are detailed in Table 2.

619

620 Table 2. Primers used for qPCR of *chrna5*, and housekeeping genes.

Gene Accession #	Gene symbol	Primer 5' 3'
β-actin1 NM_131031.2	*actb1*	(F) AGATGACACAGATCATGTTCGAGA (R) CCAGTAGTACGACCAGAAGCG
Elongation factor I-alpha FJ915061.1	*ef1a*	(F) CTGGAGGCCAGCTCAAACAT (R) ATCAAGAAGAGTAGTACCGCTAGCATT
chrna5 ENSDARG00000003420	*chrna5*	(F) ATGGTAACAGCTCTCAGCTTGGT (R) TTAGCTAGTAATTTCAGCATAGC
chrnb4 ENSARG00000101677	*chrnb4*	(F) TCCTGTGTGTGTGTATGTGAATG (R) TCACATGCCGTCCCGTCTG
chrna3 ENSDARG00000100991.2	*chrna3*	(F) CCTCCTGTGTCCGACTGAAC (R) CTTCCAGTCATCCTGGACCTC

621

622 Reactions were performed using an Applied Biosystems 7500 Real-Time PCR system, in 96-well plate
623 format. The cycling conditions were as follows: 95°C for 10m to activate, then 40 cycles of 95°C for 15s,
624 60°C for 30s. After completion, a melt curve was run at 65-95°C for 5 seconds per step. All PCR
625 efficiencies were between 90-110%. Primer specificity was validated by a single peak on the post-PCR
626 melt curve and single-band after electrophoresis. The relative gene expression levels were normalised to
627 the housekeeping genes and analysed using the adjusted delta-delta CT method, described by
628 Hellemans and Mortier et al. (2007). All data were analysed as described below.

629 Statistical analyses

630 Data in this study were analysed and presented following the principles of hybrid effect size plus *p* value
631 [113,114]. Briefly, a P value as a measure of significance is improved upon by the supplementary
632 reporting of effect sizes, means, and 95% confidence intervals [114]. The assumptions of
633 homoscedasticity and normality typically recommended for parametric testing were not met
634 consistently for the SAZA data. As such, unpaired data were compared by non-parametric Cliff's delta
635 effect size and two-sided permutation T-tests (5000 reshuffles) with a significance level of 0.05.
636 Repeated measures data were compared by mean difference and paired permutation tests under the

637 same parameters. Vibration assay longitudinal data were analysed using a linear mixed effects model,
638 with pixels travelled as the response variable, genotype and vibration intensity as fixed effects, and
639 individual ID as a random effect to account for repeated measures. Analyses were performed in R using
640 the 'dabestr' (v2024.12.24) and 'lmerTest' (v3.1-3) packages. If multiple comparisons were made, family
641 wise error was corrected for by applying the Holm-Bonferroni step down method to *p*-values. Outputs of
642 these statistical analyses can be found in supplementary tables. Where data were presented as Gardner-
643 Altman and Cummings estimation plots, the results are reported as Cliff's delta, or Paired mean
644 difference = X, 95% CI [lower, upper], *p* = Y. For Cliff's delta, effect sizes greater than ± 0.4 and a *p*-value
645 of < 0.01 were considered meaningful and practically relevant in this study. Smaller Cliff's delta effect
646 sizes of ± 0.2 to 0.4 with accompanying *p*-value of < 0.05 were considered provisionally meaningful,
647 pending reproduction or further investigation [115,116].
648

649 ### Hybridisation chain reaction, RNA-fluorescent in-situ hybridisation (HCR™ RNA-FISH)

650 Larval zebrafish for HCR™ RNA-FISH 3.0 (HCR) [117] were collected as follows. During development,
651 300µL of 0.3% PTU (Phenylthiocarbamide, Sigma) was added to each petri dish containing larvae every
652 alternative day from 3 dpf until 14 dpf to reduce pigmentation. Following this, larvae were quickly rinsed
653 with 1x PBST, euthanized and fixed in 4% formaldehyde, diluted in 1X PBST, at room temperature for 60
654 minutes with shaking. Once fixed, the larvae were washed with 1X PBST for three minutes, three times.
655 Larvae were then permeabilized using a detergent solution (1% SDS, 0.5% Tween 20, 150mM NaCl, 1mM
656 EDTA, 0.05M Tris-HCL, pH 7.5) at 37°C for 30 minutes and washed for three minutes, three times each
657 with 1X PBST and then 5X SSCT. Finally, the larvae were transferred to 30% probe hybridization buffer
658 (30% formamide, 9mM citric acid, 0.1% Tween 20, 50µg/mL heparin, 1x Denhardt's solution, 5X SSC) and
659 incubated at 37°C for 30 minutes. At this stage, the larvae were stored at 4 degrees for up to one month
660 in the dark or used directly for HCR.
661 HCR probes against *chrna5*, *neurod1*, and *nrp1a* were prepared using an in-house Excel-based program
662 and synthesized by IDT (see Table S1 for details). Probes were prepared in a cocktail containing 30ul (10
663 µM) of each probe set against each gene in 1000 µl of 30% probe hybridization buffer. The in-situ
664 hybridization experiments were carried out in an automated robotic fluidics system. The larvae were
665 transferred to the automated fluidics robot with the primary, secondary, and wash buffers, and a script
666 to perform the reaction was loaded (preprogrammed in the system). The larvae were first incubated
667 with the probes at 37°C for 8 hrs, then washed five times with 30% probe wash buffer (30% formamide,
668 9mM citric acid, 0.1% Tween 20, 50µg/mL heparin, 5x SSC) at 37°C and then 5X SSCT twice. For the
669 secondary reaction, HCR hairpins diluted and prepared in an amplification buffer (5X SSC, 0.1% Tween
670 20, 2.5% dextran sulphate) were added and incubated for 3 hours in the dark in the automated system.
671 The larvae were then washed with 5X SSCT, eight times, for 2 mins each. After the reaction, the samples
672 were removed from the chamber and mounted with the cover slip on the dorsal side in 70% glycerol-
673 based mounting media and imaged on an Olympus FV3000 confocal microscope with the settings
674 consistent between fish. Images were post-processed first on Olympus viewer FLUOVIEW FV31S-SW
675 software with linear intensity adjustments of 150 - 4095 for all genes. Images presented for *nrp1a*,
676 *neurod1* and *chrna5* had no further processing beyond cropping to the ROI and addition of scale bars.

677 ## Protein extraction

678 Protein was extracted from the brains of adult fish, aged 6 months. The fish were euthanized, then
679 subsequently dissected in 1x PBS pH 7.0. Brain tissue was transferred to 400 µl of cold, 6 M urea buffer
680 with added protease inhibitors, and homogenized until the solution was clear of visible debris. The
681 protein samples were then briefly vortexed and centrifuged for 30 seconds to pellet debris. The samples
682 were then sonicated with three 30 second pulses at one minute intervals using a probe sonicator on ice.
683 The samples were then incubated on ice for 20 minutes before centrifuging at 14,000 rpm for 20
684 minutes at 4 °C. The supernatant was then transferred to a new tube, aliquoted, and stored in -80°C
685 until further use. Protein concentrations were measured using the Pierce BCA Protein assay kit (Thermo
686 Fisher Scientific), following the manufacturer's protocol in 96 well plate format. BSA standards were
687 serially diluted in 6M urea buffer from a working concentration of 2000 µg/ml to 25 µg/ml to create a
688 standard curve. In each well, 25 µl of diluted BSA standard or protein sample was added, and each
689 topped up by 200µl of BCA working solution. The plate was covered and incubated for 37°C for 30
690 minutes, before absorbance at 562 nm was determined by a plate reader. From one round of protein
691 extraction, approximately 0.8 mg/ml was extracted.

692 ## Western blots

693 Western blots were performed on extracted brain proteins by Wes system (ProteinSimple, product
694 number 004-600) using a 12-230 kDa Separation Module 13-capillary cartridge SM-W002. Samples were
695 diluted to 1 µg/µL in 6 M urea buffer, mixed in fluorescent 5x Master Mix, including DTT, and denatured
696 at 95°C for five minutes. The samples, primary antibodies (1:1000 diluted in Wes antibody diluent), HRP-
697 conjugated secondary antibody (1:4000 diluted in Wes antibody diluent), and chemiluminescent
698 substrate (luminol-S and peroxide) were added onto the plate, in addition to the biotinylated ladder,
699 antibody diluent and wash buffer included on the plate by the manufacturer. Default instrument
700 settings were used, stacking and separation at 475V for 30 minutes, blocking 5 minutes, primary
701 antibody incubation, 60 minutes, and secondary antibody incubation, 30 minutes. The
702 chemiluminescence detection was set for 30 minutes total, with imaging at 2-minute intervals. The
703 electropherograms were first checked to see if manual correction was needed for peak detection, and
704 then the band intensity results were exported. The following primary antibodies were used: for the
705 reference protein, monoclonal anti-Tubulin antibody, beta, clone KMX-1 (MAB3408) Sigma, produced in
706 mice. For *chrna5*, Monoclonal anti-CHRNA5 antibody (AV34967-100UG) Sigma, produced in rabbit, Table
707 2.3.3.3. The secondary antibodies used were polyclonal anti-mouse goat antibody (P0447 DAKO) HRP
708 conjugated and polyclonal Anti-rabbit (sc-2004 Santa Cruz Biotechnology), produced in goat HRP
709 Conjugated.

710 ## Light/Dark preference assay

711 The light/dark preference assay, designed to test nyctophobia/photophila as a proxy for anxiety, was set
712 up and performed as described by [118] and [119]. Four transparent rectangular plastic boxes (70mm x
713 40mm x 15mm, L x W x H) were each filled with 50ml of system water. The boxes were placed inside a
714 cabinet, covered with a cloth to prevent any light interference. Each box was divided into light and dark
715 sides, each 35 mm in length, by using an iPad (Apple 7th generation, display at highest light intensity)

underneath to project an equal light/dark split image (Figure 6 (**a**)). A camera (ACa2040-90 uM USB 3.0: Basler resolution 800 x 600 pixels) with infrared filter was placed overhead, which recorded the movements of 12-14 dpf larvae. To prevent social interference, dividers were placed in between the four chambers to isolate the fish completely. The setup was further illuminated by placing two infrared LED bars on either side of the tanks (Figure 6). The camera output was recorded using Pylon viewer Ver 6.1.1. All trials were conducted between 9am-6pm. Prior to the assay, larvae were either not treated with any stimulus. The larvae were quickly and gently added to the illuminated rectangular boxes, with one larva per box, four boxes at a time. A total of ~36 individuals per treatment and genotype were assayed. Larvae were allowed to acclimate in the chamber for ten minutes until free, uninhibited swimming was observed before starting the video recording. Then, the larvae were filmed for ten minutes in complete light, followed by a further ten minutes in the light and dark setting (Figure 6(**a**)). Each fish was tracked in real time by an in-house custom-written Python code using the opencv library [118]. Each recording lasted 10,000 frames at 16 fps, totalling approximately 10 minutes. The x-y coordinates of each larva in each frame were exported. Automated analyses [118] were applied to all larvae, however, individuals that moved less than 50 mm during the total assay duration were excluded from the final data.

Circadian Rhythm assay

The circadian assay was performed in 48-well plates, with each well containing 1ml of system water. These plates were placed inside an opaque rectangular box to avoid outside light interference, on top of an illuminated light box, surrounded by four IR LED bars (LBS2-00-080-2-IR850-24V, 850nm: TMS Lite). A camera (Aca2040- 90µM USB 3.0: Basler) with an IR filter was positioned above the plate to track the movement of each 7-10 dpf larva. At the onset of recording, ~15:00-15:30 pm, the larvae were kept in continuous ambient light. The illumination was switched off at 22:30 pm, and switched on again at 08:30 am the next day, and the assay ended after 24 hours. Larval movements were tracked by an in-house custom-written script in Python 2.7 [120], incorporating functions from the OpenCV library to control the Arduino microcontroller and video track larvae movement. Videos were captured at 576 x 854 px at 10 fps, and the background subtraction method was applied to obtain the X and Y coordinates of the fish. The protocol is further described in detail in [120]. The following key metrics were quantified: total seconds spent moving per minute, mean velocity, mean resting period, and average distance moved per fish. Activity thresholds were defined as such: an active bout was indicated when the larvae moved five seconds or more per minute. Meanwhile, a resting, or inactive bout, was indicated when larvae moved four seconds or less for one minute. For the assay duration, larvae were either not treated with any stimulus. Two other behavioural assays were also conducted during the circadian assay duration, testing the startle responses to light/dark, and to vibration. The light/dark startle response test occurred for five, 30 minute light/dark cycles for a total of five hours, from ~17.30 – 22.30 pm (Figure 6(**j-l**)). The vibration test consisted of six, 20 minute cycles, two per hour. Within these cycles, 18 shocks were administered per hour for nine different intensities, first from 0-100% ascending, and subsequently descending, from a period of ~1:00-7:00 am (Figure 6(**i**)). Vibrations were controlled through a speaker via an Arduino microcontroller board by a custom Python script (Python 2.7, C[120]. The highest intensity was represented by 50% on the computer audio output. The time interval between each vibration was 30 seconds, which prevented behavioural habituation. The larvae were recorded as

757 responding if they moved more than 7 pixels (~ 4 mm), and the average percentage of responding fish
758 was calculated for each different intensity. The observed values were corrected against baseline
759 locomotor activity, as further described by [120].

760 Feeding Assay

761 Food types for the various feeding assays were prepared as follows. *Paramecium caudatum* was
762 cultured and harvested weekly as described in the zebrafish book [121], and '*Paramecium* Recipes for
763 Large and Small Facilities'. Briefly, paramecia culture supernatants were collected in a clean 50 ml falcon
764 tube to remove any yeast accumulated at the bottom, then centrifuged (Eppendorf) at 4°C, 15 minutes,
765 2500 rpm to isolate the pellet. The resulting supernatant was removed and the paramecia pellet was
766 resuspended in 1 mL of system water. Next, 2.5 µL of stock DID dye (Invitrogen) in 22.5 µL 100% ethanol
767 was added to the resuspended paramecia and incubated for two hours at RT under nutation.
768 Subsequently, the mixture was centrifuged at 13,000 rpm for five minutes at RT. The alcohol
769 supernatant was removed, and the pellet resuspended in 1mL of system water under nutation for 15
770 minutes. The mixture was then briefly vortexed and added onto the rotator again for a further ten
771 minutes to thoroughly mix the paramecia with system water. Finally, 1mL of this dyed paramecia
772 solution was added to 3 mL of system water and used to feed four plates of larvae (1 mL per plate). Egg
773 yolk from chicken (#cat E0625 Sigma) was purchased and prepared as described for the paramecia, but
774 with the following adjustments. For egg yolk powder, 10mg was measured and mixed with 1ml of
775 system water and 1 µL DID stock dye. The tube was vortexed and incubated for 2 hours at RT under
776 nutation. Subsequently, the supernatant was removed, without disturbing the pellet. The pellet was
777 then resuspended in 1 ml of system water under nutation for 15 minutes, ready for use. The protein-rich
778 powder, custom formulated and a gift from Caroline Wee lab, was prepared in the same manner as the
779 egg yolk powder.
780 To perform the assay with paramecia, the larvae were subjected to two "training days" of feeding in the
781 assay petri dish with 1ml of paramecia (30-40 larvae per petri dish) overnight. The assay was performed
782 at 7 dpf. Larvae were first fed with excess unlabelled paramecia for 90 minutes during the first feeding
783 session, then washed and fasted for 120 minutes. After the fasting period, the larvae were transferred
784 into smaller, 35mm petri dishes, each filled with 4 mL of system water, before adding 1 mL of labelled
785 paramecia. Larvae were given 90 minutes for the second feeding session, after which they were cold
786 anaesthetized and fixed in 4% PFA in 1x PBST overnight at 4°C. Larvae were washed three times in 1x
787 PBST the next day before mounting and imaging (Figure 6 (**m**)).
788 The assay was performed in a similar manner with egg yolk or protein-rich powder as the food, but with
789 the following adjustments. On the training days at 5 and 6 dpf, the fish were instead fed with a small
790 quantity of 150/250 micro ground dry algae (Zeitger) for 30 minutes. The algae were then washed away,
791 and replaced with fresh system water overnight. At 7 dpf, the first feeding session lasted for only 30
792 minutes, before the fasting period of 2 hours. For the second feeding session, 500µl of labelled-egg yolk,
793 or protein rich powder, was added in petri dishes for 30 minutes, before fixing. To prepare for imaging,
794 the fixed larvae were washed three times in 1x PBS and arranged per genotype (25-30 fish) in a 35mm
795 glass bottom dish in a circular pattern, avoiding larvae touching each other. To measure the amount of
796 food consumed by larvae, the intestinal fluorescence signal was captured using a Leica M205 FA
797 fluorescent stereoscope. Corresponding brightfield and fluorescent images were captured, Cy5 filter 651

nm, in a covered, dark room. The brightfield images were captured at 20 ms exposure at 40% intensity, whilst Cy5/mcherry exposure was 100ms, 100% intensity. The fluorescence intensity was measured by an in-house written code developed by Cheng et al. [120], which correlated to the total amount of food consumed by each larva. The segmentation method used for fluorescence quantification has been described in full by [120], and the code is maintained and can be found at https://github.com/CarolineWeeLab/EZgut [120]. The mean fluorescence intensity was obtained for each larva and normalized against the controls.

Supplementary Materials:

Contains 9 supplementary figures and 10 supplementary tables.

Author Contributions:

Conceptualization, A.S.M, T.G, and J.R; methodology, T.G., C.K., T.D.B, J.R. and J.W.C.; formal analysis, T.G, J.R.; investigation, T.G., J.R., and C.K., J.W.C; resources, A.S.M; writing—original draft preparation, T.G., and J.R; writing—review and editing, All.; visualisation, T.G. and J.R.; supervision, A.S.M.; project administration, A.S.M; funding acquisition, A.S.M.

Funding:

This research was supported by the Ministry of Education (MOE), Singapore (through grant number T2EP30220-0020), Yale-NUS College (through grant numbers IG16-LR003, IG18-SG103, IG19-BG106, and SUG), and National University of Singapore Yong Loo Lin School of Medicine Dean's Office (through grant number NUHSRO/2025/031/NUSMed/003/LOA), and by National University of Singapore Institute of Digital Medicine (through grant number WisDM/Seed/003/2025) to ASM.

Data Availability Statement:

The datasets used to generate the figures are included within the article and its additional file(s). Additional data are available from the corresponding author upon request.

Acknowledgments:

We would like to thank the zebrafish fish facility (ZFF) staff at the IMCB, A*STAR for their assistance with fish husbandry; Drs. Ruey Kuang-Cheng and Caroline Wee for assistance with conducting circadian rhythm and appetite regulation assays; Li Xinrui for generating customized Python analysis scripts.

Conflicts of Interest:

The authors declare no conflict of interest. The sponsors had no role in the design, execution, interpretation, or writing of the study.

References:

1. Witkiewitz, K.; Litten, R.Z.; Leggio, L. Advances in the Science and Treatment of Alcohol Use Disorder. *Sci Adv* **2019**, *5*, eaax4043.

2. Moeller, G.; Terplan, M. *Substance Use Disorders*; Oxford University Press, USA, 2020; ISBN 9780190920197.
3. Rehm, J.; Shield, K.D. Global Burden of Disease and the Impact of Mental and Addictive Disorders. *Curr. Psychiatry Rep.* **2019**, *21*, 10.
4. CDCTobaccoFree Fast Facts Available online: https://www.cdc.gov/tobacco/data_statistics/fact_sheets/fast_facts/index.htm (accessed on 22 July 2020).
5. GBD 2019 Tobacco Collaborators Spatial, Temporal, and Demographic Patterns in Prevalence of Smoking Tobacco Use and Attributable Disease Burden in 204 Countries and Territories, 1990-2019: A Systematic Analysis from the Global Burden of Disease Study 2019. *Lancet* **2021**, *397*, 2337–2360.
6. Larsson, S.C.; Burgess, S. Appraising the Causal Role of Smoking in Multiple Diseases: A Systematic Review and Meta-Analysis of Mendelian Randomization Studies. *EBioMedicine* **2022**, *82*, 104154.
7. Li, M.D.; Burmeister, M. New Insights into the Genetics of Addiction. *Nat. Rev. Genet.* **2009**, *10*, 225–231.
8. Picciotto, M.R.; Kenny, P.J. Mechanisms of Nicotine Addiction. *Cold Spring Harb Perspect Med* **2021**, *11*, doi:10.1101/cshperspect.a039610.
9. Miller, A.P.; Baranger, D.A.A.; Paul, S.E.; Garavan, H.; Mackey, S.; Tapert, S.F.; LeBlanc, K.H.; Agrawal, A.; Bogdan, R. Neuroanatomical Variability and Substance Use Initiation in Late Childhood and Early Adolescence. *JAMA Netw Open* **2024**, *7*, e2452027.
10. Pichardo, F.; Wilson, S. The Adolescent Brain Cognitive Development Study and How We Think About Addiction. *JAMA Netw Open* **2024**, *7*, e2451997.
11. Thorgeirsson, T.E.; Geller, F.; Sulem, P.; Rafnar, T.; Wiste, A.; Magnusson, K.P.; Manolescu, A.; Thorleifsson, G.; Stefansson, H.; Ingason, A.; et al. A Variant Associated with Nicotine Dependence, Lung Cancer and Peripheral Arterial Disease. *Nature* **2008**, *452*, 638–642.
12. Spitz, M.R.; Amos, C.I.; Dong, Q.; Lin, J.; Wu, X. The CHRNA5-A3 Region on Chromosome 15q24-25.1 Is a Risk Factor Both for Nicotine Dependence and for Lung Cancer. *J. Natl. Cancer Inst.* **2008**, *100*, 1552–1556.
13. Jensen, K.P.; DeVito, E.E.; Herman, A.I.; Valentine, G.W.; Gelernter, J.; Sofuoglu, M. A CHRNA5 Smoking Risk Variant Decreases the Aversive Effects of Nicotine in Humans. *Neuropsychopharmacology* **2015**, *40*, 2813–2821.
14. Icick, R.; Forget, B.; Cloëz-Tayarani, I.; Pons, S.; Maskos, U.; Besson, M. Genetic Susceptibility to Nicotine Addiction: Advances and Shortcomings in Our Understanding of the CHRNA5/A3/B4 Gene Cluster Contribution. *Neuropharmacology* **2020**, *177*, 108234.
15. Lee, S.-H.; Ahn, W.-Y.; Seweryn, M.; Sadee, W. Combined Genetic Influence of the Nicotinic Receptor Gene Cluster CHRNA5/A3/B4 on Nicotine Dependence. *BMC Genomics* **2018**, *19*, 826.
16. Ware, J.J.; van den Bree, M.; Munafò, M.R. From Men to Mice: CHRNA5/CHRNA3, Smoking Behavior and Disease. *Nicotine & Tobacco Research* **2012**, *14*, 1291–1299.
17. Morton, G.; Nasirova, N.; Sparks, D.W.; Brodsky, M.; Sivakumaran, S.; Lambe, E.K.; Turner, E.E. Chrna5-Expressing Neurons in the Interpeduncular Nucleus Mediate Aversion Primed by Prior Stimulation or Nicotine Exposure. *J Neurosci* **2018**, *38*, 6900–6920.
18. Fowler, C.D.; Lu, Q.; Johnson, P.M.; Marks, M.J.; Kenny, P.J. Habenular α5 Nicotinic Receptor Subunit Signalling Controls Nicotine Intake. *Nature* **2011**, *471*, 597–601.
19. Exley, R.; McIntosh, J.M.; Marks, M.J.; Maskos, U.; Cragg, S.J. Striatal α5 Nicotinic Receptor Subunit Regulates Dopamine Transmission in Dorsal Striatum. *J Neurosci* **2012**, *32*, 2352–2356.
20. Mathuru, A.S. A Little Rein on Addiction. *Semin. Cell Dev. Biol.* **2018**, *78*, 120–129.
21. Fowler, C.D.; Tuesta, L.; Kenny, P.J. Role of α5* Nicotinic Acetylcholine Receptors in the Effects of Acute and Chronic Nicotine Treatment on Brain Reward Function in Mice. *Psychopharmacology (Berl)* **2013**, doi:10.1007/s00213-013-3235-1.

880 22. Wang, J.C.; Grucza, R.; Cruchaga, C.; Hinrichs, A.L.; Bertelsen, S.; Budde, J.P.; Fox, L.; Goldstein, E.;
881 Reyes, O.; Saccone, N.; et al. Genetic Variation in the CHRNA5 Gene Affects mRNA Levels and Is
882 Associated with Risk for Alcohol Dependence. *Mol Psychiatry* **2009**, *14*, 501–510.
883 23. Venkatesh, S.K.; Stangl, B.L.; Quijano Cardé, N.A.; De Biasi, M.; Ramchandani, V.A. 36344 Effect of
884 CHRNA5 Genetic Variation and Smoking on Alcohol Related Phenotypes in Healthy Adult Drinkers. *J.*
885 *Clin. Transl. Sci.* **2021**, *5*, 2–3.
886 24. Dawson, A.; Wolstenholme, J.T.; Roni, M.A.; Campbell, V.C.; Jackson, A.; Slater, C.; Bagdas, D.;
887 Perez, E.E.; Bettinger, J.C.; De Biasi, M.; et al. Knockout of Alpha 5 Nicotinic Acetylcholine Receptors
888 Subunit Alters Ethanol-Mediated Behavioral Effects and Reward in Mice. *Neuropharmacology* **2018**,
889 *138*, 341–348.
890 25. Santos, N.; Chatterjee, S.; Henry, A.; Holgate, J.; Bartlett, S.E. The α5 Neuronal Nicotinic
891 Acetylcholine Receptor Subunit Plays an Important Role in the Sedative Effects of Ethanol but Does
892 Not Modulate Consumption in Mice. *Alcohol Clin Exp Res* **2013**, *37*, 655–662.
893 26. Besson, M.; Forget, B.; Correia, C.; Blanco, R.; Maskos, U. Profound Alteration in Reward Processing
894 due to a Human Polymorphism in CHRNA5: A Role in Alcohol Dependence and Feeding Behavior.
895 *Neuropsychopharmacology* **2019**, *44*, 1906–1916.
896 27. Frie, J.A.; Nolan, C.J.; Murray, J.E.; Khokhar, J.Y. Addiction-Related Outcomes of Nicotine and
897 Alcohol Co-Use: New Insights Following the Rise in Vaping. *Nicotine Tob Res* **2022**, *24*, 1141–1149.
898 28. Mondoloni, S.; Nguyen, C.; Vicq, E.; Ciscato, M.; Jehl, J.; Durand-de Cuttoli, R.; Torquet, N.; Tolu, S.;
899 Pons, S.; Maskos, U.; et al. Prolonged Nicotine Exposure Reduces Aversion to the Drug in Mice by
900 Altering Nicotinic Transmission in the Interpeduncular Nucleus. *Elife* **2023**, *12*,
901 doi:10.7554/eLife.80767.
902 29. Gentry, C.L.; Lukas, R.J. Regulation of Nicotinic Acetylcholine Receptor Numbers and Function by
903 Chronic Nicotine Exposure. *Curr Drug Targets CNS Neurol Disord* **2002**, *1*, 359–385.
904 30. Liu, M.; Guo, S.; Huang, D.; Hu, D.; Wu, Y.; Zhou, W.; Song, W. Chronic Alcohol Exposure Alters Gene
905 Expression and Neurodegeneration Pathways in the Brain of Adult Mice. *J Alzheimers Dis* **2022**, *86*,
906 315–331.
907 31. Kutlu, M.G.; Gould, T.J. Nicotine Modulation of Fear Memories and Anxiety: Implications for
908 Learning and Anxiety Disorders. *Biochem. Pharmacol.* **2015**, *97*, 498–511.
909 32. Watanabe, S.; Hofman, M.A.; Shimizu, T. *Evolution of the Brain, Cognition, and Emotion in*
910 *Vertebrates*; Springer, **2017**; ISBN 9784431565598.
911 33. Wullimann, M.F.; Rupp, B.; Reichert, H. *Neuroanatomy of the Zebrafish Brain: A Topological Atlas*;
912 Springer, **1996**; ISBN 9783764351205.
913 34. von Trotha, J.W.; Vernier, P.; Bally-Cuif, L. Emotions and Motivated Behavior Converge on an
914 Amygdala-like Structure in the Zebrafish. *Eur J Neurosci* **2014**, *40*, 3302–3315.
915 35. Cully, M. Zebrafish Earn Their Drug Discovery Stripes. *Nat Rev Drug Discov* **2019**, *18*, 811–813.
916 36. Egan, R.J.; Bergner, C.L.; Hart, P.C.; Cachat, J.M.; Canavello, P.R.; Elegante, M.F.; Elkhayat, S.I.;
917 Bartels, B.K.; Tien, A.K.; Tien, D.H.; et al. Understanding Behavioral and Physiological Phenotypes of
918 Stress and Anxiety in Zebrafish. *Behav. Brain Res.* **2009**, *205*, 38–44.
919 37. Frøland Steindal, I.A.; Whitmore, D. Circadian Clocks in Fish-What Have We Learned so Far? *Biology*
920 *(Basel)* **2019**, *8*, doi:10.3390/biology8010017.
921 38. Wee, C.L.; Song, E.Y.; Johnson, R.E.; Ailani, D.; Randlett, O.; Kim, J.-Y.; Nikitchenko, M.; Bahl, A.;
922 Yang, C.-T.; Ahrens, M.B.; et al. A Bidirectional Network for Appetite Control in Larval Zebrafish.
923 *Elife* **2019**, *8*, doi:10.7554/eLife.43775.
924 39. Klee, E.W.; Schneider, H.; Clark, K.J.; Cousin, M.A.; Ebbert, J.O.; Hooten, W.M.; Karpyak, V.M.;
925 Warner, D.O.; Ekker, S.C. Zebrafish: A Model for the Study of Addiction Genetics. *Hum. Genet.* **2012**,
926 *131*, 977–1008.
927 40. Nathan, F.M.; Kibat, C.; Goel, T.; Stewart, J.; Claridge-Chang, A.; Mathuru, A.S. Contingent Stimulus

928 Delivery Assay for Zebrafish Reveals a Role for CCSER1 in Alcohol Preference. *Addict Biol* **2022**, *27*,
929 e13126.
930 41. Raine, J.; Kibat, C.; Banerjee, T.D.; Monteiro, A.; Mathuru, A. *chrna3* modulates Biphasic Response
931 to Alcohol. *bioRxiv* **2024**.
932 42. Schneider, H.; Pearson, A.; Harris, D.; Krause, S.; Tucker, A.; Gardner, K.; Chinyanya, K. Identification
933 of Nicotine-Seeking and Avoiding Larval Zebrafish Using a New Three-Choice Behavioral Assay.
934 *Front Mol Neurosci* **2023**, *16*, 1112927.
935 43. Bossé, G.D.; Peterson, R.T. Development of an Opioid Self-Administration Assay to Study Drug
936 Seeking in Zebrafish. *Behav. Brain Res.* **2017**, *335*, 158–166.
937 44. Jumper, J.; Evans, R.; Pritzel, A.; Green, T.; Figurnov, M.; Ronneberger, O.; Tunyasuvunakool, K.;
938 Bates, R.; Žídek, A.; Potapenko, A.; et al. Highly Accurate Protein Structure Prediction with
939 AlphaFold. *Nature* **2021**, *596*, 583–589.
940 45. Marks, M.J.; Pauly, J.R.; Gross, S.D.; Deneris, E.S.; Hermans-Borgmeyer, I.; Heinemann, S.F.; Collins,
941 A.C. Nicotine Binding and Nicotinic Receptor Subunit RNA after Chronic Nicotine Treatment. *J*
942 *Neurosci* **1992**, *12*, 2765–2784.
943 46. Hong, E.; Santhakumar, K.; Akitake, C.A.; Ahn, S.J.; Thisse, C.; Thisse, B.; Wyart, C.; Mangin, J.-M.;
944 Halpern, M.E. Cholinergic Left-Right Asymmetry in the Habenulo-Interpeduncular Pathway. *Proc*
945 *Natl Acad Sci U S A* **2013**, *110*, 21171–21176.
946 47. Hua, Y.; Habicher, J.; Carl, M.; Manuel, R.; Boije, H. Novel Transgenic Zebrafish Lines to Study the
947 CHRNA3-B4-A5 Gene Cluster. *Dev Neurobiol* **2025**, *85*, e22956.
948 48. Banerjee, T.D.; Raine, J.; Mathuru, A.S.; Chen, K.H.; Monteiro, A. Spatial mRNA Profiling Using Rapid
949 Amplified Multiplexed-FISH (RAM-FISH). *bioRxiv* **2024**.
950 49. Hahn, B.; Stolerman, I.P. Nicotine-Induced Attentional Enhancement in Rats: Effects of Chronic
951 Exposure to Nicotine. *Neuropsychopharmacology* **2002**, *27*, 712–722.
952 50. Dani, J.A.; Harris, R.A. Nicotine Addiction and Comorbidity with Alcohol Abuse and Mental Illness.
953 *Nat Neurosci* **2005**, *8*, 1465–1470.
954 51. Schlaepfer, I.R.; Hoft, N.R.; Ehringer, M.A. The Genetic Components of Alcohol and Nicotine Co-
955 Addiction: From Genes to Behavior. *Curr Drug Abuse Rev* **2008**, *1*, 124–134.
956 52. Fluharty, M.; Taylor, A.E.; Grabski, M.; Munafò, M.R. The Association of Cigarette Smoking With
957 Depression and Anxiety: A Systematic Review. *Nicotine Tob Res* **2017**, *19*, 3–13.
958 53. Sharma, P.; Nelson, R.J. Disrupted Circadian Rhythms and Substance Use Disorders: A Narrative
959 Review. *Clocks Sleep* **2024**, *6*, 446–467.
960 54. Audrain-McGovern, J.; Benowitz, N.L. Cigarette Smoking, Nicotine, and Body Weight. *Clin*
961 *Pharmacol Ther* **2011**, *90*, 164–168.
962 55. Olfson, E.; Saccone, N.L.; Johnson, E.O.; Chen, L.-S.; Culverhouse, R.; Doheny, K.; Foltz, S.M.; Fox, L.;
963 Gogarten, S.M.; Hartz, S.; et al. Rare, Low Frequency and Common Coding Variants in CHRNA5 and
964 Their Contribution to Nicotine Dependence in European and African Americans. *Mol Psychiatry*
965 **2016**, *21*, 601–607.
966 56. Pandey, N.; Pal, S.; Sharma, L.K.; Guleria, R.; Mohan, A.; Srivastava, T. SNP rs16969968 as a Strong
967 Predictor of Nicotine Dependence and Lung Cancer Risk in a North Indian Population. *Asian Pac J*
968 *Cancer Prev* **2017**, *18*, 3073–3079.
969 57. Chen, L.-S.; Xian, H.; Grucza, R.A.; Saccone, N.L.; Wang, J.C.; Johnson, E.O.; Breslau, N.; Hatsukami,
970 D.; Bierut, L.J. Nicotine Dependence and Comorbid Psychiatric Disorders: Examination of Specific
971 Genetic Variants in the CHRNA5-A3-B4 Nicotinic Receptor Genes. *Drug Alcohol Depend* **2012**, *123*
972 *Suppl 1*, S42–S51.
973 58. Levin, E.D.; Bencan, Z.; Cerutti, D.T. Anxiolytic Effects of Nicotine in Zebrafish. *Physiol Behav* **2007**,
974 *90*, 54–58.
975 59. Gebauer, D.L.; Pagnussat, N.; Piato, A.L.; Schaefer, I.C.; Bonan, C.D.; Lara, D.R. Effects of Anxiolytics

976 in Zebrafish: Similarities and Differences between Benzodiazepines, Buspirone and Ethanol.
977 *Pharmacol Biochem Behav* **2011**, *99*, 480–486.
978 60. Gilman, J.M.; Ramchandani, V.A.; Davis, M.B.; Bjork, J.M.; Hommer, D.W. Why We like to Drink: A
979 Functional Magnetic Resonance Imaging Study of the Rewarding and Anxiolytic Effects of Alcohol. *J*
980 *Neurosci* **2008**, *28*, 4583–4591.
981 61. Picciotto, M.R.; Brunzell, D.H.; Caldarone, B.J. Effect of Nicotine and Nicotinic Receptors on Anxiety
982 and Depression. *Neuroreport* **2002**, *13*, 1097–1106.
983 62. Steenbergen, P.J.; Richardson, M.K.; Champagne, D.L. Patterns of Avoidance Behaviours in the
984 Light/dark Preference Test in Young Juvenile Zebrafish: A Pharmacological Study. *Behav Brain Res*
985 **2011**, *222*, 15–25.
986 63. O'Hara, B.F.; Edgar, D.M.; Cao, V.H.; Wiler, S.W.; Heller, H.C.; Kilduff, T.S.; Miller, J.D. Nicotine and
987 Nicotinic Receptors in the Circadian System. *Psychoneuroendocrinology* **1998**, *23*, 161–173.
988 64. Jaehne, A.; Loessl, B.; Bárkai, Z.; Riemann, D.; Hornyak, M. Effects of Nicotine on Sleep during
989 Consumption, Withdrawal and Replacement Therapy. *Sleep Med Rev* **2009**, *13*, 363–377.
990 65. Garcia, A.N.; Salloum, I.M. Polysomnographic Sleep Disturbances in Nicotine, Caffeine, Alcohol,
991 Cocaine, Opioid, and Cannabis Use: A Focused Review. *Am J Addict* **2015**, *24*, 590–598.
992 66. Gibson, M.; Munafò, M.R.; Taylor, A.E.; Treur, J.L. Evidence for Genetic Correlations and
993 Bidirectional, Causal Effects Between Smoking and Sleep Behaviors. *Nicotine Tob Res* **2019**, *21*,
994 731–738.
995 67. Steriade, M. Acetylcholine Systems and Rhythmic Activities during the Waking--Sleep Cycle. *Prog*
996 *Brain Res* **2004**, *145*, 179–196.
997 68. Grunberg, N.E. The Effects of Nicotine and Cigarette Smoking on Food Consumption and Taste
998 Preferences. *Addict Behav* **1982**, *7*, 317–331.
999 69. Hofstetter, A.; Schutz, Y.; Jéquier, E.; Wahren, J. Increased 24-Hour Energy Expenditure in Cigarette
1000 Smokers. *N Engl J Med* **1986**, *314*, 79–82.
1001 70. Stojakovic, A.; Espinosa, E.P.; Farhad, O.T.; Lutfy, K. Effects of Nicotine on Homeostatic and Hedonic
1002 Components of Food Intake. *J Endocrinol* **2017**, *235*, R13–R31.
1003 71. Calarco, C.A.; Li, Z.; Taylor, S.R.; Lee, S.; Zhou, W.; Friedman, J.M.; Mineur, Y.S.; Gotti, C.; Picciotto,
1004 M.R. Molecular and Cellular Characterization of Nicotinic Acetylcholine Receptor Subtypes in the
1005 Arcuate Nucleus of the Mouse Hypothalamus. *Eur J Neurosci* **2018**, doi:10.1111/ejn.13966.
1006 72. Calarco, C.A.; Picciotto, M.R. Nicotinic Acetylcholine Receptor Signaling in the Hypothalamus:
1007 Mechanisms Related to Nicotine's Effects on Food Intake. *Nicotine Tob Res* **2020**, *22*, 152–163.
1008 73. Breum, A.W.; Falk, S.; Svendsen, C.S.A.; Nicolaisen, T.S.; Mathiesen, C.V.; Maskos, U.; Clemmensen,
1009 C. Divergent Roles of α5 and β4 Nicotinic Receptor Subunits in Food Reward and Nicotine-Induced
1010 Weight Loss in Male Mice. *Endocrinology* **2022**, *163*, bqac079.
1011 74. Tochon, L.; Henkous, N.; Besson, M.; Maskos, U.; David, V. Distinct Chrna5 Mutations Link Excessive
1012 Alcohol Use to Types I/II Vulnerability Profiles and IPN GABAergic Neurons. *Transl Psychiatry* **2024**,
1013 *14*, 461.
1014 75. Choi, M.; Aliev, F.; Barr, P.B.; Cooke, M.E.; Kuo, S.I.; Salvatore, J.E.; Dick, D.M.; Brislin, S.J. Genetic,
1015 Psychological, and Environmental Factors Are Uniquely Associated with Onset of Alcohol Use in the
1016 Adolescent Brain Cognitive Development (ABCD) Study. *Transl Psychiatry* **2025**, *15*, 229.
1017 76. Giniatullin, R.; Nistri, A.; Yakel, J.L. Desensitization of Nicotinic ACh Receptors: Shaping Cholinergic
1018 Signaling. *Trends Neurosci* **2005**, *28*, 371–378.
1019 77. Lüscher, C.; Malenka, R.C. Drug-Evoked Synaptic Plasticity in Addiction: From Molecular Changes to
1020 Circuit Remodeling. *Neuron* **2011**, *69*, 650–663.
1021 78. Kolokotroni, K.Z.; Rodgers, R.J.; Harrison, A.A. Effects of Chronic Nicotine, Nicotine Withdrawal and
1022 Subsequent Nicotine Challenges on Behavioural Inhibition in Rats. *Psychopharmacology (Berl)* **2012**,
1023 *219*, 453–468.

1024 79. Peartree, N.A.; Hatch, K.N.; Goenaga, J.G.; Dado, N.R.; Molla, H.; Dufwenberg, M.A.; Campagna, A.;
1025 Mendoza, R.; Cheung, T.H.C.; Talboom, J.S.; et al. Social Context Has Differential Effects on
1026 Acquisition of Nicotine Self-Administration in Male and Female Rats. *Psychopharmacology (Berl)*
1027 **2017**, *234*, 1815–1828.
1028 80. Exposure to an Enriched Environment Reduces Alcohol Self-Administration in Sardinian Alcohol-
1029 Preferring Rats. *Physiology & Behavior* **2022**, *249*, 113771.
1030 81. Johnson, M.C.; Zweig, J.A.; Zhang, Y.; Ryabinin, A.E. Effects of Social Housing on Alcohol Intake in
1031 Mice Depend on the Non-Social Environment. *Front Behav Neurosci* **2024**, *18*, 1380031.
1032 82. Chellian, R.; Behnood-Rod, A.; Wilson, R.; Lin, K.; King, G.W.-Y.; Bruijnzeel, A.W. Dopamine D1-like
1033 Receptor Activation Decreases Nicotine Intake in Rats with Short or Long Access to Nicotine. *Addict*
1034 *Biol* **2023**, *28*, e13312.
1035 83. Ross, J.T.; Corrigall, W.A.; Heidbreder, C.A.; LeSage, M.G. Effects of the Selective Dopamine D3
1036 Receptor Antagonist SB-277011A on the Reinforcing Effects of Nicotine as Measured by a
1037 Progressive-Ratio Schedule in Rats. *Eur J Pharmacol* **2007**, *559*, 173–179.
1038 84. Kenny, P.J.; Chartoff, E.; Roberto, M.; Carlezon, W.A., Jr; Markou, A. NMDA Receptors Regulate
1039 Nicotine-Enhanced Brain Reward Function and Intravenous Nicotine Self-Administration: Role of
1040 the Ventral Tegmental Area and Central Nucleus of the Amygdala. *Neuropsychopharmacology*
1041 **2009**, *34*, 266–281.
1042 85. Blokhina, E.A.; Kashkin, V.A.; Zvartau, E.E.; Danysz, W.; Bespalov, A.Y. Effects of Nicotinic and NMDA
1043 Receptor Channel Blockers on Intravenous Cocaine and Nicotine Self-Administration in Mice. *Eur*
1044 *Neuropsychopharmacol* **2005**, *15*, 219–225.
1045 86. Champtiaux, N.; Gotti, C.; Cordero-Erausquin, M.; David, D.J.; Przybylski, C.; Léna, C.; Clementi, F.;
1046 Moretti, M.; Rossi, F.M.; Le Novère, N.; et al. Subunit Composition of Functional Nicotinic Receptors
1047 in Dopaminergic Neurons Investigated with Knock-out Mice. *J Neurosci* **2003**, *23*, 7820–7829.
1048 87. Zuo, L.; Tan, Y.; Li, C.-S.R.; Wang, Z.; Wang, K.; Zhang, X.; Lin, X.; Chen, X.; Zhong, C.; Wang, X.; et al.
1049 Associations of Rare Nicotinic Cholinergic Receptor Gene Variants to Nicotine and Alcohol
1050 Dependence. *Am J Med Genet B Neuropsychiatr Genet* **2016**, *171*, 1057–1071.
1051 88. Gotti, C.; Zoli, M.; Clementi, F. Brain Nicotinic Acetylcholine Receptors: Native Subtypes and Their
1052 Relevance. *Trends Pharmacol Sci* **2006**, *27*, 482–491.
1053 89. Thorgeirsson, T.E.; Gudbjartsson, D.F.; Surakka, I.; Vink, J.M.; Amin, N.; Geller, F.; Sulem, P.; Rafnar,
1054 T.; Esko, T.; Walter, S.; et al. Sequence Variants at CHRNB3-CHRNA6 and CYP2A6 Affect Smoking
1055 Behavior. *Nat Genet* **2010**, *42*, 448–453.
1056 90. Yang, J.; Wang, S.; Yang, Z.; Hodgkinson, C.A.; Iarikova, P.; Ma, J.Z.; Payne, T.J.; Goldman, D.; Li,
1057 M.D. The Contribution of Rare and Common Variants in 30 Genes to Risk Nicotine Dependence. *Mol*
1058 *Psychiatry* **2015**, *20*, 1467–1478.
1059 91. Hoft, N.R.; Corley, R.P.; McQueen, M.B.; Huizinga, D.; Menard, S.; Ehringer, M.A. SNPs in CHRNA6
1060 and CHRNB3 Are Associated with Alcohol Consumption in a Nationally Representative Sample.
1061 *Genes Brain Behav* **2009**, *8*, 631–637.
1062 92. García-Martín, E.; Ramos, M.I.; Cornejo-García, J.A.; Galván, S.; Perkins, J.R.; Rodríguez-Santos, L.;
1063 Alonso-Navarro, H.; Jiménez-Jiménez, F.J.; Agúndez, J.A.G. Missense Gamma-Aminobutyric Acid
1064 Receptor Polymorphisms Are Associated with Reaction Time, Motor Time, and Ethanol Effects.
1065 *Front Cell Neurosci* **2018**, *12*, 10.
1066 93. Cui, W.-Y.; Seneviratne, C.; Gu, J.; Li, M.D. Genetics of GABAergic Signaling in Nicotine and Alcohol
1067 Dependence. *Hum Genet* **2012**, *131*, 843–855.
1068 94. Doyon, W.M.; Dong, Y.; Ostroumov, A.; Thomas, A.M.; Zhang, T.A.; Dani, J.A. Nicotine Decreases
1069 Ethanol-Induced Dopamine Signaling and Increases Self-Administration via Stress Hormones.
1070 *Neuron* **2013**, *79*, 530–540.
1071 95. Grieder, T.E.; George, O.; Tan, H.; George, S.R.; Le Foll, B.; Laviolette, S.R.; van der Kooy, D. Phasic

1072 D1 and Tonic D2 Dopamine Receptor Signaling Double Dissociate the Motivational Effects of Acute
1073 Nicotine and Chronic Nicotine Withdrawal. *Proc Natl Acad Sci U S A* **2012**, *109*, 3101–3106.
1074 96. Wilar, G.; Shinoda, Y.; Sasaoka, T.; Fukunaga, K. Crucial Role of Dopamine D2 Receptor Signaling in
1075 Nicotine-Induced Conditioned Place Preference. *Mol Neurobiol* **2019**, *56*, 7911–7928.
1076 97. Yan, Y.; Pushparaj, A.; Le Strat, Y.; Gamaleddin, I.; Barnes, C.; Justinova, Z.; Goldberg, S.R.; Le Foll, B.
1077 Blockade of Dopamine d4 Receptors Attenuates Reinstatement of Extinguished Nicotine-Seeking
1078 Behavior in Rats. *Neuropsychopharmacology* **2012**, *37*, 685–696.
1079 98. Connor, J.P.; Young, R.M.; Lawford, B.R.; Saunders, J.B.; Ritchie, T.L.; Noble, E.P. Heavy Nicotine and
1080 Alcohol Use in Alcohol Dependence Is Associated with D2 Dopamine Receptor (DRD2)
1081 Polymorphism. *Addict Behav* **2007**, *32*, 310–319.
1082 99. Luciano, M.; Zhu, G.; Kirk, K.M.; Whitfield, J.B.; Butler, R.; Heath, A.C.; Madden, P.A.F.; Martin, N.G.
1083 Effects of Dopamine Receptor D4 Variation on Alcohol and Tobacco Use and on Novelty Seeking:
1084 Multivariate Linkage and Association Analysis. *Am J Med Genet B Neuropsychiatr Genet* **2004**, *124B*,
1085 113–123.
1086 100. Thanos, P.K.; Katana, J.M.; Ashby, C.R., Jr; Michaelides, M.; Gardner, E.L.; Heidbreder, C.A.; Volkow,
1087 N.D. The Selective Dopamine D3 Receptor Antagonist SB-277011-A Attenuates Ethanol
1088 Consumption in Ethanol Preferring (P) and Non-Preferring (NP) Rats. *Pharmacol Biochem Behav*
1089 **2005**, *81*, 190–197.
1090 101. Agrawal, A.; Pergadia, M.L.; Saccone, S.F.; Hinrichs, A.L.; Lessov-Schlaggar, C.N.; Saccone, N.L.;
1091 Neuman, R.J.; Breslau, N.; Johnson, E.; Hatsukami, D.; et al. Gamma-Aminobutyric Acid Receptor
1092 Genes and Nicotine Dependence: Evidence for Association from a Case-Control Study. *Addiction*
1093 **2008**, *103*, 1027–1038.
1094 102. Xuei, X.; Flury-Wetherill, L.; Dick, D.; Goate, A.; Tischfield, J.; Nurnberger, J., Jr; Schuckit, M.;
1095 Kramer, J.; Kuperman, S.; Hesselbrock, V.; et al. GABRR1 and GABRR2, Encoding the GABA-A
1096 Receptor Subunits rho1 and rho2, Are Associated with Alcohol Dependence. *Am J Med Genet B*
1097 *Neuropsychiatr Genet* **2010**, *153B*, 418–427.
1098 103. Zhao, B.; Zhu, Y.; Wang, W.; Cui, H.-M.; Wang, Y.-P.; Lai, J.-H. Analysis of Variations in the Glutamate
1099 Receptor, N-Methyl D-Aspartate 2A (GRIN2A) Gene Reveals Their Relative Importance as Genetic
1100 Susceptibility Factors for Heroin Addiction. *PLoS One* **2013**, *8*, e70817.
1101 104. MacPhail, R.C.; Brooks, J.; Hunter, D.L.; Padnos, B.; Irons, T.D.; Padilla, S. Locomotion in Larval
1102 Zebrafish: Influence of Time of Day, Lighting and Ethanol. *Neurotoxicology* **2009**, *30*, 52–58.
1103 105. Fernandes, A.M.; Fero, K.; Arrenberg, A.B.; Bergeron, S.A.; Driever, W.; Burgess, H.A. Deep Brain
1104 Photoreceptors Control Light-Seeking Behavior in Zebrafish Larvae. *Curr Biol* **2012**, *22*, 2042–2047.
1105 106. Wexler, Y.; Huang, D.; Medvetzky, A.; Armbruster, D.; Driever, W.; Yan, J.; Gothilf, Y. Zebrafish Dark-
1106 Dependent Behavior Requires Phototransduction by the Pineal Gland. *J Pineal Res* **2024**, *76*,
1107 e70021.
1108 107. Lamiré, L.A.; Haesemeyer, M.; Engert, F.; Granato, M.; Randlett, O. Functional and Pharmacological
1109 Analyses of Visual Habituation Learning in Larval Zebrafish. *Elife* **2023**, *12*, doi:10.7554/eLife.84926.
1110 108. Bianco, I.H.; Kampff, A.R.; Engert, F. Prey Capture Behavior Evoked by Simple Visual Stimuli in Larval
1111 Zebrafish. *Front Syst Neurosci* **2011**, *5*, 101.
1112 109. Mineur, Y.S.; Abizaid, A.; Rao, Y.; Salas, R.; DiLeone, R.J.; Gündisch, D.; Diano, S.; De Biasi, M.;
1113 Horvath, T.L.; Gao, X.-B.; et al. Nicotine Decreases Food Intake through Activation of POMC
1114 Neurons. *Science* **2011**, *332*, 1330–1332.
1115 110. Zhu, S.I.; Goodhill, G.J. From Perception to Behavior: The Neural Circuits Underlying Prey Hunting in
1116 Larval Zebrafish. *Front. Neural Circuits* **2023**, *17*, 1087993.
1117 111. Hwang, W.Y.; Fu, Y.; Reyon, D.; Maeder, M.L.; Tsai, S.Q.; Sander, J.D.; Peterson, R.T.; Yeh, J.-R.J.;
1118 Joung, J.K. Efficient Genome Editing in Zebrafish Using a CRISPR-Cas System. *Nat. Biotechnol.* **2013**,
1119 *31*, 227–229.

112. Krishnan, S.; Mathuru, A.S.; Kibat, C.; Rahman, M.; Lupton, C.E.; Stewart, J.; Claridge-Chang, A.; Yen, S.-C.; Jesuthasan, S. The Right Dorsal Habenula Limits Attraction to an Odor in Zebrafish. *Curr. Biol.* **2014**, *24*, 1167–1175.
113. Goodman, W.M.; Spruill, S.E.; Komaroff, E. A Proposed Hybrid Effect Size plus *p*-Value Criterion: Empirical Evidence Supporting Its Use. *Am. Stat.* **2019**, *73*, 168–185.
114. Ho, J.; Tumkaya, T.; Aryal, S.; Choi, H.; Claridge-Chang, A. Moving beyond P Values: Data Analysis with Estimation Graphics. *Nat. Methods* **2019**, *16*, 565–566.
115. Goodman, W.M.; Spruill, S.E.; Komaroff, E. A Proposed Hybrid Effect Size plus *p*-Value Criterion: Empirical Evidence Supporting Its Use. *Am. Stat.* **2019**, *73*, 168–185.
116. Cliff, N. Dominance Statistics: Ordinal Analyses to Answer Ordinal Questions. *Psychol. Bull.* **1993**, *114*, 494–509.
117. Choi, H.M.T.; Schwarzkopf, M.; Fornace, M.E.; Acharya, A.; Artavanis, G.; Stegmaier, J.; Cunha, A.; Pierce, N.A. Third-Generation Hybridization Chain Reaction: Multiplexed, Quantitative, Sensitive, Versatile, Robust. *Development* **2018**, *145*, doi:10.1242/dev.165753.
118. Cheng, R.-K.; Krishnan, S.; Jesuthasan, S. Activation and Inhibition of tph2 Serotonergic Neurons Operate in Tandem to Influence Larval Zebrafish Preference for Light over Darkness. *Sci. Rep.* **2016**, *6*, 20788.
119. Jesuthasan, S.; Krishnan, S.; Cheng, R.-K.; Mathuru, A. Neural Correlates of State Transitions Elicited by a Chemosensory Danger Cue. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **2021**, *111*, 110110.
120. Cheng, R.-K.; Tan, J.X.M.; Chua, K.X.; Tan, C.J.X.; Wee, C.L. Osmotic Stress Uncovers Correlations and Dissociations Between Larval Zebrafish Anxiety Endophenotypes. *Front. Mol. Neurosci.* **2022**, *15*, 900223.
121. ZFIN: Zebrafish Book: Growing Zebrafish Available online: https://zfin.org/zf_info/zfbook/chapt3/3.3.html (accessed on 10 July 2025).


a
NH₂
COOH
Extracellular
Intracellular
TM1
TM2
TM3
TM4
5bp deletion
WT
GCTATTAACATCCACCATCGCTCCTCTTCCACCCATCATAGC
Ala Ile Asn Ile His His Arg Ser Ser Ser Thr His His Ser
chrna5-/-
GCTATTAACATCCACC-----TCCTCTTCCACCCATCATAG
Ala Ile Asn Ile His Leu Leu Phe His Pro Ser *
1074 bp
AA 325
5bp deletion
b
WT
chrna5-/-
NH₂
COOH
Extracellular
Intracellular
TM2
TM1
TM3
TM4
5bp deletion
c
WT
chrna5-/-
Relative Expression
2.0
1.5
1.0
0.5
0.0
n = 7
n = 8
Cliff's delta
1.0
0.5
0.0
−0.5
−1.0
d
Prosencephalon
Rhombencephalon
Pineal gland & Habeunula
OB
Eye
Tel
dHbL
Pl
dHbR
Tor
TeO
Ce
imMO
ifMO
dHb
DAPI
nrp1a
chrna5
merge
Rostral
Caudal
50µm
20µm


a
Self Administration for Zebrafish Assay (SAZA)
3.5 cm
7.5 cm
In
In
Out
Stimulus ROI
Control ROI
Stimulus
Control
Self-admin (18')
Pre (3')
Post (3')
Stimulus
Control
Volume dispensed (Vol)
(Stimulus Vol - Control Vol)
(Stimulus Vol + Control Vol)
=
Preference Index
-1.0
+1.0
Control
Stimulus
SAZA
WT 0μM Nicotine
WT x̄ 0.5μM Nicotine
WT x̄ 25μM Nicotine
chrna5-/- 0μM Nicotine
chrna5-/- x̄ 0.5μM Nicotine
chrna5-/- x̄ 25μM Nicotine
b
c
Preference Index
Cliff's delta
n = 30
n = 30
n = 30
n = 29
n = 30
n = 30
Nicotine Self Administration
d
Preference Index
Cli's delta
n = 30
n = 29
n = 30
n = 30
n = 30
n = 30
e
WT
f
chrna5 -/-
Preference index
Entries into stimulus
Time in stimulus
Mean time per stimulus entry
Mean velocity in stimulus
Time in control
0μM
x̄25μM
Cliffs Delta
Alcohol Self Administration
SAZA
WT 0% Alcohol
WT x̄ 0.25% Alcohol
WT x̄ 0.125% Alcohol
WT x̄ 0.5% Alcohol
chrna5-/- 0% Alcohol
chrna5-/- x̄ 0.25% Alcohol
chrna5-/- x̄ 0.125% Alcohol
chrna5-/- x̄ 0.5% Alcohol
g
h
i
Preference Index
Cliff's delta
n = 30
n = 31
n = 28
n = 28
n = 31
n = 28
n = 29
n = 28
n = 30
n = 31
n = 31
n = 28
n = 28
n = 29
n = 28
n = 28
j
WT
k
chrna5 -/-
Preference index
Entries into stimulus
Time in stimulus
Mean time per stimulus entry
Mean velocity in stimulus
Time in control
0%
x̄0.5%
Cliffs Delta


Pretreatment scheme
Day 1- 7 ~20 dpf
Day 8 ~28 dpf
a
Pretreatment
Nicotine
Alcohol
Self-administration
Nicotine
Alcohol
Nicotine pretreatment
Nicotine Self-administration
Alcohol pretreatment
Nicotine Self-administration
Nicotine pretreatment
Alcohol Self-administration
Alcohol pretreatment
Alcohol Self-administration
b
System water
1% Alcohol
1μM Nicotine
1 Hour incubation
c
Brain dissection & RNA sequencing
Self-administration assay
Stimulus
Out
Control
In
In

Nicotine Pretreatment





Alcohol Pretreatment








Light/Dark Anxiety Assay
a
Dorsal view
Visible light source
Dark
Light
Opaque divider
Infrared LED
Opaque container
b
WT
chrna5-/-
Time Spent in the dark (%)
n = 32
n = 32
Cliff's delta
c
Number of Entries to dark Side
n = 32
n = 32
d
First entry to dark Cumulative Percentage (%)
Time (seconds)
Circadian Rhythm Assay
e
Dorsal view
Visible light source
Tracking
Infrared LED
Speaker
Opaque container
Tracking
WT
chrna5-/-
Light/Dark transition assay
Vibration assay
START
END
15:00
17:30
22:30
1:00
7:00
8:30
15:00
f
WT
15:00 - 22:30
22:30 - 8:30
8:30 - 15:00
Time inactive (m)
n = 45
n = 45
n = 45
Cliff's delta
g
chrna5-/-
15:00 - 22:30
22:30 - 8:30
8:30 - 15:00
Time inactive (m)
n = 48
n = 48
n = 48
Cliff's delta
h
chrna5-/-
WT
Time inactive (m)
Cliff's delta
15:00 - 22:30
22:30 - 8:30
8:30 - 15:00
i
WT
n = 270
chrna5-/-
n = 288
Cumulative pixels travelled ± 95% CI
Vibration intensity (%)
j
WT
n = 225
chrna5-/-
n = 240
Mean locomotor activity (mm, ± 95% CI)
Time (m)
k
Light -> Dark transition (0m)
Mean locomotor activity (mm)
WT
n = 225
chrna5-/-
n = 240
Delta
Paired mean difference
l
Dark -> light transition (30m)
Mean locomotion distance (mm)
WT
n = 225
chrna5-/-
n = 240
Delta
Paired mean difference
Feeding and Appetite Assay
m
7 dpf - Pre-feeding
Unlabelled food
Wash
1.5h
2h
Starvation
7 dpf - Final feed
DID labelled food
Filter and fix
Quantify gut fluorescence
1.5h
Overnight
n
Egg Yolk
WT
chrna5-/-
Mean flourescence intensity
n = 301
n = 278
Cliff's delta
o
Protein
n = 267
n = 256
p
Paramecia
n = 297
n = 289